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Animal models have been useful in the study of prostate biology and 
disease for decades, with continuous refinement and renewal to improve utility 
and comparative accuracy. This work describes two advances in murine models 
of prostate development and disease, and details the application of these new 
models to discover critical aspects of prostate biology. 
 The mechanisms driving epithelial differentiation, proliferation, and 
invasion during prostate development have been postulated to provide critical 
insight into similar processes occurring in prostate cancer. Investigations into 
gene function at the earliest stages of prostate development were limited by the 
lack of suitable methods for controlled, tissue specific deletion of genes in the 
urogenital sinus. To remedy this problem, we employed tamoxifen-dependent 
conditional mutagenesis and developed a method to rapidly and efficiently 
delete target genes in the developing prostate with precise temporal control. 
Using this method, we describe the absolute requirement for Wnt signaling 
through beta-catenin in the initial phase of lineage commitment during prostate 
morphogenesis. 
 Inflammation promotes cancer initiation and progression in a variety of 
organs, and has been linked epidemiologically to prostate cancer. Limitations in 
animal models of prostatitis have hindered efforts to produce definitive evidence 
that inflammation promotes cancer progression. Here, we characterize the 
immunologic and morphologic changes induced in the prostate by a new model 
of murine bacterial prostatitis. This model uses CP1, a strain of Escherichia coli 
recently isolated from a human and described in acute studies of murine pelvic 
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pain. CP1 induces chronic prostatitis lasting at least one year, with epithelial 
hyperplasia and immune cell infiltration.  Using this model, we show chronic 
inflammation accelerates prostate cancer progression in the Hi-Myc model of 
murine prostate cancer and provide the first definitive link between prostate 
inflammation and prostate cancer progression. 
 A single process unites these two seemingly disparate projects: 
recognizing a gap in scientific knowledge, fashioning a model that can be used to 
fill this gap, and finally applying these models to uncover basic and translational 
aspects of prostate biology. Together, the data presented here expand the 
understanding of prostate biology and provide new tools for future inquiry. 
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Animal models of prostate disease 
Aging men experience prostate diseases at a high frequency. The incidence of 
lower urinary tract symptoms (LUTS), usually associated with benign prostatic 
hypertrophy or BPH, increases steadily with age, and almost half of men experience 
symptoms by 65 years of age [1]. Prostate cancer is similarly common, with autopsy 
studies reporting undiagnosed cases of prostate cancer present in more than 30 percent 
of men in their 50s [2]. Prostate inflammation, linked to both prostate cancer and BPH, 
may have an even higher incidence than either disease, and has been proposed to 
initiate or accelerate the development of both BPH and cancer.  However, the natural 
history of these diseases remains poorly understood.  Epidemiologic studies have found 
multiple genetic and environmental factors may affect prostate disease, from the general 
health effects of diet and obesity, to specific genetic risk factors, such as HOXB13 
mutations [3]. Despite these studies, differentiating indolent from lethal prostate cancer 
and identifying factors that contribute to each remains a challenge. 
 Answering these questions in human research is difficult because the necessary 
studies are often not feasible or would be unethical.  For these reasons, a substantial 
portion of our understanding of prostate biology and disease stems from research using 
animal models.  From dogs to rodents, these models rely on anatomical and 
physiological relevance to human disease, and have benefited from constant refinement.  
Historically, dogs were used extensively to study prostate hypertrophy and prostate 
cancer, as this is one of the few species in which these diseases spontaneously occur [4].  
However, prostate disease in dogs takes years to develop, and occurs at a lower rate 
than humans [5]. The more recent development of genetically modified mice has led to 
an explosion in the use of mouse models of prostate disease.  Mice develop spontaneous 
prostate disease at a very low rate, making them a “blank slate” on which to determine 
what role environmental and genetic manipulations play in the development of prostate 
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disease. The effects these factors have on the time course and penetrance of 
carcinogenesis and metastasis have been determined by transgenic mice, which provide 
predictable and reproducible models of prostate cancer. 
 
 Comparative anatomy of the mouse and human prostate 
 An understanding of the similarities and an appreciation of the differences 
between mouse and human prostate anatomy should support and guide the use of 
murine models of prostate biology.  In both species, the prostate is an accessory sex 
organ that develops from the urogenital sinus (Fig. 1).  The formation and maintenance 
of the prostate requires androgens, and the mature organ in both species is a lobular 
secretory gland with basal, luminal, and neuroendocrine cell types.  However, 
significant differences in anatomy and histology should be recognized to appropriately 
interpret mouse studies. 
 In the embryo, prostate development is similar in the human and mouse, with 
distinct lobes arising from precise anatomic locations in the urogenital sinus.  The 
human prostate rapidly adopts a compact structure with a thick fibromuscular stroma, 
while the mouse prostate retains a loose, lobular appearance with scant stroma (Fig. 2).  
Although not divided into lobes, the adult human prostate is divided into recognizable 
zones, which have a consistent anatomic arrangement and are histologically distinct.  
The lobes have differential susceptibilities to pathology, with BPH arising primarily in 
transition zone and cancer arising most in the peripheral zone [6].  Mouse prostate lobes 
are similarly distinct histologically (Fig. 3A&B), with distinct gene expression profiles 
and secretory products. Some rodent models of prostate disease show lobe predilection, 
but the pronounced lobe specific pathology in genetically engineered models of prostate  
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Figure 1. Prostate Bud Formation in the Urogenital Sinus 
The urogenital sinus (UGS) is located caudal to the bladder.  At embryonic day 17.5 
(E17.5) the urogenital sinus epithelium (UGE) adopts a prostatic identity and invades 
into the urogenital sinus mesenchyme (UGM). 
5 
Figure 2. Mouse Urogenital Tract Gross Anatomy 
The mouse prostate is divided into distinct bilaterally symmetric lobes named for their 
anatomic location, which arise from the urethra at the base of the bladder (BL).  Anterior 
prostate (AP), ventral prostate (VP), lateral prostate (LP), and dorsal prostate (DP) are of 
urogenital sinus origin.  The much larger seminal vesicles (SV) originate from the 
Wolffian ducts.  
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cancer may be attributed to differential transgene expression, rather than differences in 
biology.  In fact, prostate pathology of any kind is extremely rare in the mouse, with 
spontaneous carcinoma described only in case reports, and epithelial hyperplasia or 
inflammation reported to occur in 1 percent and 5 percent of mice, respectively [7]. In 
both species, the majority of cells have a basal or luminal phenotype, but the relative 
number and distribution are somewhat different in the mouse.  Whereas basal cells in 
the normal human prostate gland form a near continuous layer upon which the luminal 
cells rest, basal cells in the mouse form an incomplete layer and form a smaller 
proportion of the total epithelium (Fig. 3C). 
 
Tools for mouse models of development and disease 
 A variety of genetically engineered lines of mice have been developed for use in 
studies of prostate development and disease.  Traditional knockout or mutant lines of 
mice, arising spontaneously or through targeted homologous recombination, involve 
somatic mutations that delete or inactivate a single gene in all tissues.  Although these 
mutations have been useful for the study of gene function, they can be of limited use in 
the prostate due to effects on other organs. Inactivation of tumor suppressors, such as 
p53, APC, or PTEN, results in tumor formation in other organs prior to the onset of 
significant prostate pathology.  For developmental studies, homozygous gene deletion is 
often embryonic lethal prior to prostate morphogenesis.  For these reasons, tools for 
conditional or tissue specific mutagenesis were developed.   
 Conditional mutagenesis is most commonly accomplished with the Cre-LoxP 
system.  This system uses a bacterial recombinase that recognizes LoxP sites inserted 
into the genome, brings them together, and excises the intervening DNA.  This system  
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Figure 3. Mouse Prostate Histology 
(A,B) Mouse prostate lobes can be recognized by their distinct histologic appearance.  
Glands from the dorsal prostate (DP) show moderate infolding, granular cytoplasm, and 
bright eosinophilic homogenous secretions.  Glands from the lateral prostate (LP) have 
sparse infoldings and granular or particulate eosinophilic secretions, and ventral 
prostate (VP) glands have rare infoldings with large lumens and pale serous secretions. 
(C) Immunohistochemistry for keratin 14 (CK14) highlights an incomplete rim of basal 
cells adjacent to the basement membrane in a normal prostate gland. 
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can be used to delete a gene or activate a transgene if the intervening sequence contains 
a stop codon.  This deletion can be controlled with expression of Cre by a prostate-
specific promoter or with a drug dependent expression system.  The most commonly 
used prostate specific promoters are Probasin [8], Nkx3.1 [9], and Hoxb13 [10].  Although 
these promoters drive expression specifically in the prostate, they all suffer from extra-
prostatic expression. Additionally, these promoters drive Cre expression beginning at 
different times and in different, but overlapping, sets of epithelial cells (Table 1). 
Probasin-Cre is useful for carcinogenesis experiments as expression begins after 
postnatal day 14 and will not interfere with early prostate morphogenesis.  However, 
this promoter drives epithelial Cre expression in a mosaic fashion, and shows strong 
expression in the stroma and seminal vesicles (Fig. 4).  Furthermore, Probasin-Cre can be 
expressed in the ovary, and maternally inherited Cre may result in mosaic 
recombination [11]. Nkx3.1 and Hoxb13 promoters drive expression in embryogenesis, 
which is useful for developmental studies, but can preclude carcinogenesis studies if 
deletion of the targeted gene interferes with prostate morphogenesis.  To remedy this, 
investigators have used conditional mutagenesis, which is dependent on drug 
treatment.  The two most widely used methods involve tamoxifen-dependent Cre, and 
Tet-on/off systems.  Both require drugs for activation, but Tet-on/off systems have the 
advantage of being reversible once Tetracycline treatment is withdrawn. 
 
Mouse models of prostatitis 
A variety of potential causes have been associated with prostatic inflammation in 
humans, including hormonal changes, dietary factors, autoimmune responses, and 
infectious agents [12].  To understand the mechanisms underlying chronic prostatitis, 






















































Table 1. A Comparison of Prostate-Specific Promoters 
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Figure 4. Probasin Promoter Driven Cre Recombinase Expression 
(A,B) Probasin-Cre (PB-Cre4) R26R LacZ reporter mouse shows diffuse Cre expression 
in the lateral prostate (LP), but the arrow indicates sparse, mosaic expression in the 
ventral prostate (VP).  (C) Cre expression is evident in the epithelium as well as stromal 
cells (arrow). 
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factors. Several strains of rats and mice have been identified with a high incidence of 
spontaneous nonbacterial prostatitis.  The Lewis strain of rat in particular, has a 60-70% 
incidence of prostatitis as young as 12 weeks of age [13]. In mice, the Non-Obese 
Diabetic (NOD) strain of mice develops a high incidence of prostatitis [14].  This strain is 
particularly sensitive to autoimmune disease in many organs, and prostate inflammation 
is likely a manifestation of this phenotype.  Hormones, especially estrogen, have been 
linked to autoimmune disease in women, and have been associated with an increased 
risk for prostate cancer [15, 16]. To study this association, estrogen has been used to 
initiate prostatitis in a rat model.  Neonatal Wistar rats injected with 17-beta-estradiol 
followed by testosterone develop severe prostatitis [17].  Environmental exposures may 
also affect prostate carcinogenesis. Consumption of red meat has been associated with 
prostate cancer, and may act through the formation of heterocyclic amines in the 
cooking process [18]. In rats, exposure to PhIP, a heterocyclic amine formed in cooked 
meat, results in a high incidence of DNA damage and inflammation in the prostate [19]. 
Any source of tissue damage and inflammation can release prostate epithelial antigens 
in the context of immune stimulation and could potentially initiate an autoimmune 
response.  Evidence supporting this hypothesis comes in the form of auto-reactive T cells 
in men with prostatitis [20]. Although this hypothesis is difficult to test in men, several 
rodent models of prostatitis have successfully induced prostatitis by manipulating the 
immune response.  Thymectomy three day old mice alters T cell maturation and induces 
an autoimmune response in a variety of organs, including the prostate [21].  An 
autoimmune response specific to the prostate can be initiated by vaccination with whole 
prostate lysate, or purified prostate proteins [22-24].  Transfer of specific T cells into mice 
genetically engineered to express ovalbumin can generate autoimmune prostatitis, as in 
the POET model [25]. Infectious prostatitis has been studied in rats and mice primarily 
using isolates of Escherichia coli, but also with Propionibacterium acnes [26-28].  These 
models have evolved from direct surgical injection of bacteria into the prostate to less 
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invasive means of instillation via urethral catheter.  However, the strains of E. coli most 
often used to initiate prostatitis are not prostate derived strains, but highly pathogenic 
strains isolated from septic patients [29]. 
 
5.  Project Overview 
The overall goal of this project was to understand the function of Wnt signaling 
in prostate morphogenesis, and to determine the effects of inflammation on prostate 
cancer progression.   
Chapter I examines the function of beta-catenin and Wnt signaling in early 
prostate lineage commitment. Previous work in our lab identified the Wnt pathway as 
highly differentially expressed during prostate epithelial differentiation and invasion, 
but the function of this pathway in prostate development had not been described.  A 
serious limitation to studying this, or any, pathway in prostate development was the 
lack of a well-characterized method to delete genes in a controlled fashion in the 
urogenital sinus.  To answer this question, we adapted tamoxifen-dependent Cre 
mutagenesis to use in the embryonic urogenital sinus in order to rapidly and efficiently 
delete beta-catenin.  Using this technique, we determined that Wnt signaling is critical in 
the initial cascade of signaling events initiated by androgens that result in 
undifferentiated urogenital sinus epithelium adopting prostatic identity and invading 
the surrounding mesenchyme. 
Chapter II focuses on the role of prostate inflammation in prostate cancer 
progression.  The CP1 model of prostatitis has been described in short-term experiments 
and in chronic pelvic pain, but long-term inflammation from this strain had not been 
previously described.  We characterized the immune cell infiltrate and epithelial 
changes resulting from chronic inflammation.  After adding CP1 induced-inflammation 
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to the Hi-Myc model of prostate cancer, we were able to provide the first direct evidence 
that prostate inflammation accelerates prostate cancer progression. 
These data fill a void in the understanding of prostate biology with the potential 
for expanding our understanding of prostate carcinogenesis and cancer progression.  In 
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Androgens initiate a complex network of signals within the UGS that trigger 
prostate lineage commitment and bud formation.  Given its contributions to 
organogenesis in other systems, we investigated a role for canonical Wnt 
signaling in prostate development.  We developed a new method to achieve 
complete deletion of beta-catenin, the transcriptional coactivator required for 
canonical Wnt signaling, in early prostate development.  Beta-catenin deletion 
abrogated canonical Wnt signaling and yielded prostate rudiments that exhibited 
dramatically decreased budding and failed to adopt prostatic identity. This 
requirement for canonical Wnt signaling was limited to a brief critical period 
during the initial molecular phase of prostate identity specification. Deletion of 
beta-catenin in the adult prostate did not significantly affect organ homeostasis. 
Collectively, these data establish that beta-catenin and Wnt signaling play key 





The adult rodent prostate is an exocrine gland divided into distinct lobes, 
with each lobe consisting of branching ducts and blind ending tubules. In the 
embryo, this complex structure originates from a simple cone-shaped structure 
called the urogenital sinus (UGS), which is present in both males and females 
[30]. Between embryonic days 14.5 and 17.5 (E14.5 to E17.5) in males, rising levels 
of testicular androgens act directly on urogenital sinus mesenchyme to initiate 
prostate development [31]. In particular, androgens induce a variety of 
mesenchymal signals, which instruct the adjacent urogenital sinus epithelium 
(UGE) to adopt prostatic identity, invade the surrounding mesenchyme, and 
form solid tubular buds. Although androgens play a crucial role in initiating 
prostate organogenesis from the mesenchymal compartment, the subsequent 
signaling events driving lineage commitment and branching morphogenesis 
have not been fully defined.   
Prostate bud formation at embryonic day E17.5 represents the first 
morphologic evidence of prostate development, but molecular evidence of 
prostate differentiation is present shortly after circulating androgen levels begin 
to rise. The molecular phase of prostate development is defined by the earliest 
known marker of prostatic differentiation, the homeobox gene Nkx3.1.  Nkx3.1 
expression is first detectable in the UGS around E16, when androgen is present 
but prostate buds have yet to form [32, 33]. Although Nkx3.1 expression is a 
reliable marker of prostatic differentiation, it is not required for prostate 
formation [32, 34]. This suggests other signaling pathways are responsible for 
prostate lineage commitment.  Our previous work, complemented by several 
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other studies, have identified Wnt pathway related genes as significantly 
induced by androgens at the initiation of prostatic differentiation [35-38]. 
Moreover, we have shown a link between the signaling pathways active during 
early lineage commitment and pathways aberrantly activated in prostate 
pathology.  Clearly defining the role for Wnt signaling in early prostate 
development will provide a foundation for future studies in prostate 
development, and may provide insights into prostatic disease. 
Wnt signaling is critical for cell fate determination in a variety of organs 
outside of the prostate.  For example, canonical Wnt signaling is required for 
specification of distal epithelial cells in the mouse lung [39], and is required for 
the initiation of mammary development [40].  During pancreas development, 
canonical Wnt signaling is required for exocrine lineage specification [41, 42]. In 
the prostate, investigations into roles for canonical Wnt signaling in embryonic 
prostate development are limited.  Constitutively active beta-catenin induces 
hyperplasia and prostatic intraepithelial neoplasia (mPIN) if expressed in the 
embryo [43]. The non-canonical, beta-catenin independent, Wnt pathway has 
been shown to regulate bud positioning and outgrowth through examination of 
Wnt5a knockout mice [44, 45].  Postnatal manipulation of canonical Wnt 
signaling in organ culture of rat UGSs inhibits branching, increases proliferation, 
and alters differentiation of prostate epithelium [46].   Investigations of Wnt 
function in adult cells have shown, in addition to oncogenic effects, that 
activation of canonical Wnt signaling leads to a change in cellular differentiation, 
either preventing maturation or inducing transdifferentiation into squamous 
epithelium [43, 47, 48]. Overexpression of Wif1, an antagonist of Wnt signaling, 
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in recombinant tissue grafts prevents transdifferentiation of adult bladder 
transitional epithelial cells to prostate  epithelial cells [49].  Thus, multiple lines of 
evidence indicate a potential role for canonical Wnt signaling in prostate lineage 
commitment, but the precise role of this pathway in early prostate organogenesis 
is undefined. 
Canonical Wnt signaling is activated when a Wnt ligand binds a low-
density lipoprotein receptor-related protein (LRP) and one of the frizzled (Fzd) 
transmembrane receptor family members [50].  These complex receptor-ligand 
interactions all funnel into a single transcriptional co-activator, beta-catenin, 
encoded by a single gene, Ctnnb1. Thus, deletion of Ctnnb1 can effectively silence 
canonical Wnt signaling.  Beta-catenin levels are strictly regulated through an 
elegant series of phosphorylation and degradation events. In the absence of Wnt 
ligand, cytoplasmic beta-catenin is phosphorylated and is subsequently 
ubiquitinated and targeted for proteasomal degradation [51, 52]. Wnt signaling 
inhibits phosphorylation of beta-catenin, allowing it to accumulate in the 
cytoplasm and translocate to the nucleus where it associates with TCF/LEF 
family transcription factors and regulates target gene expression. One such target 
is Axin2, a negative feedback regulator of Wnt signaling and a useful marker of 
canonical pathway activity, both generally [53] and in the prostate [54]. Unlike 
other Wnt targets that can also be induced by other pathways, Axin2 
transcription appears to be a specific indicator of canonical Wnt signaling [55]. 
Because Wnt signaling is broadly active in development, genetic modes to 
explore a role for canonical Wnt signaling in prostate lineage determination are 
challenging.  Beta-catenin germline knockout mice show severe defects at 
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gastrulation and die at E7, and thus are not useful for assessing a prostate 
phenotype at E16 and later [56]. Furthermore, existing systems for conditional 
deletion of genes in the prostate, such as Nkx3.1-Cre and Probasin-Cre, are 
expressed after prostate development has begun, so are unsuitable for studying 
lineage commitment [57, 58]. We therefore adapted a method used previously to 
study kidney development  [59] and accomplished controlled, conditional 
deletion of beta-catenin in early prostate development [60]. Tamoxifen-inducible 
Cre allows rapid and efficient deletion of target genes flanked by LoxP sites in 
vivo and in vitro.  With this method, we demonstrate an absolute requirement for 
canonical Wnt signaling in lineage commitment and bud outgrowth. 
 
Materials and Methods 
Animals 
All experimental procedures were approved by the Johns Hopkins Institutional 
Animal Care and Use Committee (IACUC).  All mouse lines were maintained on 
a C57BL/6J background.  Wildtype C57BL/6J, Ctnnb1fl/fl, NOD.SCID, and Cre-
ERT1 mice (Tamoxifen-inducible Cre inserted into Rosa26 locus) were obtained 
from Jackson Laboratories (Bar Harbor, ME, Stocks 664, 4152, 1303, and 4847).  
Probasin-Cre (Pb-Cre4) mice were obtained from NCI Mouse Repository 
(Frederick, MD).  Nkx3.1-Cre mice were a gift from Michael Shen (Columbia 
University, New York, NY).  For tamoxifen mediated deletion of beta-catenin, 
Cre-ERT1 mice were crossed with Ctnnb1fl/fl mice to generate breeder pairs 
homozygous for both mutant alleles.  For in vivo deletion of beta-catenin, Pb-
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Cre4 hemizygous, Ctnnb1fl/fl males were crossed with Ctnnb1fl/fl females.  Nkx3.1-
Cre heterozygous, Ctnnb1fl/+ males were crossed with Ctnnb1fl/fl females to generate 
Nkx3.1-Cre heterozygous, Ctnnb1fl/fl embryos.  Genotyping was performed using 
primer sets and protocols recommended by the source of each strain.  DNA for 
PCR was isolated from tails (adult mice) or liver (embryos).  
 
UGS organ culture and subcapsular renal grafts 
Timed pregnant female mice were obtained from overnight mating, with the 
following day considered E0.5.  The UGS was harvested from embryos at the 
specified ages (E15.5-E17.5) and sex was determined by gonadal inspection.  
UGSs were harvested into ice-cold serum free UGS media [DMEM-F12 (1:1) 
media (Invitrogen), supplemented with nonessential amino acids (Cellgro), ITS 
liquid media supplement (Sigma), Penicillin/Streptomycin (Invitrogen), 1 g/L 
D-glucose (Sigma), L-glutamine (Invitrogen), and 1x10-8M dihydrotestosterone 
(Sigma-Aldrich)].  After harvest, UGSs were submerged in cold UGS media for 1 
hour containing (Z)-4-hydroxytamoxifen (referred to in text as tamoxifen, Sigma-
Aldrich), PKF118-310, or vehicle (ethanol and DMSO, respectively).  Following 
treatment, the UGSs were cultured on 0.4 micron membranes (Millipore), 
oriented with the ventral surface up, overlying UGS media containing the 
indicated drugs or vehicle for 2-5 days.  Media was changed every 48 hours.  In 
all experiments, a minimum of 5 UGSs were treated per condition.  For 
subcapsular renal grafts, UGSs and prostates were similarly harvested and 
cultured for 48 hours in the presence of tamoxifen or vehicle, then grafted under 




Histology, Immunohistochemistry (IHC), and Immunofluorescence 
Tissues were fixed in formalin, routinely processed, embedded, and sectioned. 
For immunohistochemistry, the sections were deparaffinized and rehydrated 
before steaming in Target Retrieval Solution (Dako) for 40 minutes. For Nkx3.1 
staining, slides were steamed for 40 minutes in EDTA pH 9. Endogenous 
peroxidases were quenched by peroxide treatment, and the slides were blocked 
for one hour with Serum Free Protein Block (Dako). Slides were incubated with 
antibodies directed against beta-catenin (BD Biosciences, #14), E-cadherin (Cell 
Signaling, #4065), AR (Santa Cruz, N-20), FoxA2 (Cell Signaling, D56D6), Nkx3.1 
[61], or Hoxb13 [62], and visualized with ImmPRESS Polymer detection kit 
(Vector Labs).  For two color immunohistochemistry, the procedure was repeated 
and visualized with Vector VIP Peroxidase Substrate.  For immunofluorescence, 
Alexafluor conjugated secondary antibodies (Invitrogen) were applied after 
incubation with the primary antibody. 
 
Real-time reverse-transcription PCR 
To separate UGE and UGM, the UGSs were incubated in 1% Trypsin for 75 
minutes and tissue compartments were separated by fine dissection as 
previously described [63].  Total RNA was isolated using RNeasy Mini-kit 
(Qiagen) and first strand cDNA was synthesized using Ready-To-Go You-Prime 
First-Strand Beads (GE Healthcare) according to manufacturer’s directions.  
Quantitative real-time PCR was performed using Fast SYBR Green Master Mix 
(Applied Biosystems) with oligonucleotides specific for Hprt, Ctnnb1, Axin2, 
Nkx3.1, Ar, Cdh1, Fgf10, Tcf7, Foxa1, and Foxa2 (sequences listed in 
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Supplementary Table S1).  Individual expression values were normalized by 
comparison to Hprt, and relative levels of mRNA expression were calculated 
using the delta-delta Ct method [64]. 
 
Immunoblotting 
UGSs were lysed in NuPAGE LDS sample buffer and were fractionated on 
NuPAGE gels (Invitrogen).  After transfer to PVDF membranes, the samples 
were blocked and incubated with antibodies directed against beta-catenin (BD 
Biosciences, #14) and GAPDH (Santa Cruz, Clone 6C5).  Blots were developed 
using Odyssey IRDye (LI-COR Biosciences). 
 
Results 
Temporal and spatial pattern of Wnt signaling in the UGS 
Multiple components of the Wnt pathway are induced by androgens in a 
temporal and spatial pattern that suggests a role for Wnt signaling in early 
prostate development [35-38].  To understand the relationship between Wnt 
signaling and prostate lineage specification, we measured the relative expression 
of Axin2 and Nkx3.1 mRNA. UGSs were harvested at E16.5 from male and female 
embryos and mRNA was isolated from enzymatically separated UGM and UGE. 
At this time point of prostate lineage specification, when molecular prostatic 
differentiation subsequent to androgen exposure is beginning but morphologic 
changes have not begun, Axin2 transcript expression was significantly higher in 
males than in females.  Furthermore, differential expression was limited to the 
UGE (Fig. 1A), suggesting a role for Wnt in specifying the prostate epithelial 
lineage. To refine the timing of these events, we cultured androgen-naive E15.5 
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UGSs with dihydrotestosterone (DHT), a potent androgen capable of inducing 
prostatic differentiation in vitro [65], and harvested UGE after 24 and 48 hours of 
androgen exposure. Compared to controls harvested before culture, UGE 
showed significantly increased Axin2 transcript expression at both time points 
after androgen exposure, coincident with increased Nkx3.1 expression (Fig. 1B).  
Together, these observations confirm that canonical Wnt/beta-catenin signaling 
is active in UGE during the earliest phases of prostate lineage specification, 
including time points before the emergence of prostate buds. 
 
Conditional deletion of beta-catenin in the UGS 
Because germline deletion of beta-catenin is embryonic lethal, we used a 
conditional Cre-LoxP system to delete Ctnnb1, the gene encoding beta-catenin. 
E15.5 UGSs from embryos homozygous for tamoxifen-inducible Cre (CreERT1) 
and floxed beta-catenin (Ctnnb1fl/fl) were cultured with 2 mM tamoxifen or vehicle 
for 48 hours, and immunoblots were used to determine the time course and 
efficiency of gene deletion [66, 67]. Beta-catenin protein levels began to decrease 
within 24 hours of tamoxifen exposure and were nearly undetectable by the 48 
hour time point (Fig. 2A).  As expected, canonical Wnt signaling was 
dramatically suppressed after beta-catenin deletion, indicated by marked 
reduction in Axin2 and Tcf7 mRNA extracted from whole UGS cultures 48 hours 
after tamoxifen exposure (Fig. 2C).  Several other genes known to influence 
prostate development were unaffected by beta-catenin loss, including the beta-
catenin binding partner E-cadherin (Cdh1) and known mediators of prostate 
development, such as androgen receptor (Ar), Fgf10, and Foxa1 (Fig. 2C).  In 
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contrast, expression of the transcription factor Foxa2, which has been shown to be 
induced by activated beta-catenin in the prostate [43, 68], was suppressed in the 
gene-deleted UGS compared to controls. Immunohistochemistry (IHC) 
confirmed uniform deletion of beta-catenin throughout the UGS and a marked 
decrease in FoxA2 expression (Fig. 2B).  In the control group, FoxA2 expression 
closely matched Nkx3.1 expression at the UGE/UGM border and in the nascent 
buds. After beta-catenin deletion, Nkx3.1 was undetectable, and FoxA2 
expression was limited to scattered individual cells. Androgen receptor, which is 
expressed throughout the UGS in both sexes before prostate development, 
continued to be expressed in both the UGE and UGM of beta-catenin deleted 
UGSs (Fig. 2B). 
 
Loss of Wnt signaling prevents bud formation and prostate determination 
In a well established in vitro organ culture system [69], wild type controls 
showed robust bud development, whereas tamoxifen-treated beta-catenin null 
UGSs showed little or no bud formation (Fig. 3A, B).  To confirm that decreased 
budding was due to loss of canonical Wnt signaling and not a peripheral role of 
beta-catenin, we treated UGSs with the small molecule Wnt inhibitor PKF118-
310.  This drug targets the beta-catenin/TCF complex to disrupt Wnt signaling 
[70].  We observed a similar phenotype with both genetic and pharmacologic 
methods of Wnt inhibition, with significant decreases in bud number in both 
beta-catenin deleted and PKF118-310 treated UGSs compared to controls (Fig. 
3A, B).  Treatment of wildtype UGSs in organ culture with neither 2 mM 
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tamoxifen, the dose used for conditional deletion of beta-catenin, nor a log fold 
higher dose had any discernable effect on bud formation or growth (Fig. 3A, S1), 
indicating the observed effect is not from tamoxifen exposure, but loss of beta-
catenin. 
Several steps are required for prostate bud formation, most notably 
lineage commitment, followed by bud initiation and bud elongation [32].  We 
investigated the acquisition of prostate identity using immunohistochemistry for 
the prostate epithelial lineage marker Nkx3.1.  Expression of Nkx3.1 by 
immunohistochemistry was similar in control UGSs grown in vitro or in vivo, but 
beta-catenin deleted UGSs failed to express Nkx3.1, suggesting a failure of 
prostate lineage commitment (Fig. 2B).   
 
Beta-catenin deletion prevents prostate development 
Growth of UGSs as subcapsular renal grafts mirrors normal development 
in vivo, allowing assessment of long term prostate growth and maturation [69].  
After four weeks of growth in a host mouse, tamoxifen-treated grafts were 
significantly smaller than vehicle-treated controls (Fig 4A, H, S2).  Histology and 
immunohistochemical analysis showed the control grafts to be composed 
primarily of mature prostate ducts (Fig 4B-G).  The prostatic epithelium in these 
grafts expressed normal levels of beta-catenin, Nkx3.1, Hoxb13, and AR (Fig 4D-
G).  The grafts from beta-catenin deleted UGSs were examined by two 
experienced pathologists (BWS, DMB) for histologic evidence of prostatic 
differentiation.  The grafts were found to be disorganized, and did not contain 
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histologically recognizable seminal vesicle or prostatic structures (Fig 4I, J, S3).  
Immunohistochemistry showed a complete absence of beta-catenin and Nkx3.1 
expression in the tamoxifen-treated and grafted UGSs (Fig. 4K, L), confirming a 
lack of prostate differentiation.  Although Nkx3.1 is a robust marker of prostate 
lineage, its expression is regulated by androgens [71].  An androgen-independent 
marker of prostate identity can be found in Hoxb13.  Although it is more widely 
expressed in the developing embryo, expression in adult tissues is limited to 
colon and prostate [72]. All grafted tissues remained AR positive (Fig. 4N), but 
Hoxb13 expression was limited to scattered cells within areas of periurethral 
gland differentiation (Fig. 4M).  The lack of significant prostate differentiation 
and failure of bud formation confirmed that canonical Wnt/beta-catenin 
signaling is required for prostate lineage specification. 
 
After lineage commitment, prostate development can occur without beta-catenin 
 To determine if canonical Wnt signaling is continuously required for 
prostate lineage commitment or if it is only required during prostatic 
differentiation, we utilized methods to delete beta-catenin at time points after 
lineage commitment and bud initiation.  The Nkx3.1-Cre mouse has been 
indispensible for studies of prostatic development and differentiation, but 
reporter-based studies of Cre activity show expression after E17.0 [58], and 
expression of floxed target genes may not be eliminated until after E18.5 [73].  
We took advantage of this Cre expression timeline and compared deletion with 
our inducible system, giving loss of beta-catenin within 24-48 hours, to Nkx3.1-
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Cre Ctnnb1fl/fl tissues, predicted to show complete deletion at a later time point.  
The Nkx3.1-Cre cross was embryonic lethal, possibly due to expression in the 
developing sclerotome [73, 74], but we were able to harvest E15.5 UGSs and 
culture them in vitro.  In contrast to the inducible system, these UGSs were able 
to show evidence of prostatic differentiation by forming buds which lacked beta-
catenin, but expressed Nkx3.1 (Fig. 5). 
To further assess the timeline of beta-catenin dependent prostate 
differentiation, we allowed prostate development to proceed in vivo until birth, 
and harvested prostates from pups at postnatal day zero (P0), approximately five 
days after prostate development begins. These prostates were treated with 
vehicle or tamoxifen in vitro for two days to delete beta-catenin, and grown for 
four weeks as subcapsular renal grafts.  When harvested, control grafts contained 
mature prostate tissue (Fig. 6 A-D).  Tamoxifen-treated grafts showed scattered 
areas of prostatic differentiation and Nkx3.1 expression despite complete beta-
catenin deletion (Fig. 6E-H).  In addition to Nkx3.1, these grafts expressed basal 
and luminal markers (CK14, p63, CK8) in the expected pattern (Fig. S5).  
However, the SMA positive stroma was frequently discontinuous around the 
beta-catenin deleted glands. 
In order to further shorten the window of active beta-catenin signaling, 
we harvested E15.5 female UGSs for culture with DHT for 24 hours to initiate 
prostatic differentiation before deleting beta-catenin with tamoxifen.  Grown in 
vitro, UGSs harvested from male or female embryos at E15.5 show an absence of 
budding after beta-catenin deletion (Fig. S4).  However, pretreatment of these 
grafts with DHT for 24 hours before tamoxifen treatment, or physiologic in vivo 
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exposure to DHT in male embryos harvested at E16.5, resulted in rudimentary 
bud formation despite beta-catenin deletion (Fig. S4).  Grafts from these E15.5 
UGSs pretreated with DHT before tamoxifen treatment contained occasional 
mature prostate glands which maintained Nkx3.1 expression despite the absence 
of beta-catenin (Fig 6I-L).  Thus, these results indicate a window between E14.5-
E16.5 where prostatic differentiation requires canonical Wnt/beta-catenin 
signaling (Fig. 6M).  
 
Loss of beta-catenin in luminal adult epithelial cells does not affect glandular homeostasis 
In addition to roles in canonical Wnt signaling, beta-catenin  participates 
in adherens junctions by binding E-cadherin and may play a role in androgen 
signaling through interactions with AR [75, 76]. We sought to exclude the 
possibility that loss of beta-catenin would interfere with E-cadherin localization 
or androgen signaling.  To accomplish this, we examined the prostates from 12 
week old Probasin-Cre (Pb-Cre4) Ctnnb1fl/fl mice.  Probasin-driven Cre expression 
is initiated postnatally, is active in the luminal epithelial cells, and should have 
no effect on prostate determination and initial branching.  Because Probasin-Cre 
shows mosaic expression in the prostate, we were able to compare beta-catenin 
deleted and replete cells in the same gland.  Both cell types showed normal 
histology and expression of E-cadherin and AR.  Expression of the androgen-
independent differentiation marker Hoxb13 was unchanged, as was the 
androgen-dependent Nkx3.1 (Fig. 7A-D).  These data indicate that loss of beta-
catenin in adult prostate cells does not significantly affect homeostasis and 
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suggest that androgen signaling and cellular adhesion sufficient to maintain 
mature prostate glands can occur in the absence of beta-catenin. 
 
Discussion 
A variety of Wnt pathway members have been shown to be expressed in 
the developing prostate in an androgen dependent fashion.  However, the role of 
canonical Wnt signaling in early prostate development was not previously 
addressed.  Here, we show that prostate lineage specification depends on 
canonical Wnt signaling through beta-catenin, and that this signal is required at 
the earliest stages of prostate lineage commitment.  Deletion of beta-catenin or 
pharmacologic inhibition of canonical Wnt signaling blocks prostatic 
differentiation, as illustrated by a failure to initiate bud formation or form 
recognizable glandular tissue, and by undetectable levels of Nkx3.1 and greatly 
reduced Hoxb13 expression.  Previous reports indicate a role for beta-catenin in 
epithelial differentiation and cell fate determination in other organs [39-42].  Our 
findings are consistent with these reports, and suggest that Wnt mediated cell-
fate determination may be a widely conserved feature of branching 
morphogenesis.   
Investigations into the genetic programs which control prostate 
morphogenesis are limited by available strategies for conditional mutagenesis.  
Germline knockouts and other mutant mice have proven useful for studying 
some pathways, but certain mutations result in early embryonic death or prevent 
normal formation of the UGS.  Currently available models for conditional 
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mutagenesis, such as Cre-LoxP systems, are useful for studies of late embryonic 
prostate morphogenesis and adult homeostasis, but are activated too late in 
development to study the initial stages of prostate differentiation.  We show that 
conditional deletion of genes in the developing prostate can be accomplished 
rapidly and efficiently with complete temporal control. 
In addition to its role in canonical Wnt signaling, beta-catenin functions in 
cell-cell adhesion though participation in the adherens junction.  In the prostate, 
loss of beta-catenin did not effect on E-cadherin expression or localization, and 
previous reports show no interruption of adherens junctions and cell-cell 
adhesion after loss of beta-catenin [77]. A pharmacologic inhibitor of Wnt 
signaling produced similar results to genetic deletion.  Since the inhibitor affects 
transcriptional activity of beta-catenin through disruption of its association with 
Tcf/LEF family members, it should not affect adherens functions of beta-catenin.  
This result further supports the requirement for canonical Wnt signaling in 
prostate specification. 
Previously demonstrated roles of Wnt signaling in the prostate include 
postnatal regulation of branching and stem cell maintenance [46, 54].  Our 
findings do not contradict these reports, as we focused on the role of canonical 
Wnt signaling in earlier prenatal events. Prostate tissue forming from beta-
catenin deleted tissue was smaller than controls, but because we used in vitro 
organ culture and subcapsular renal grafts, we were unable to enumerate branch 
points.  We cannot make determinations about the role of Wnt signaling in 
prostatic stem cell maintenance because many of these phenotypes are evident 
only after castration and regeneration cycling of adult mice. Just as we have 
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shown a short window of absolute requirement for canonical Wnt signaling in 
early prostate development, it is reasonable to hypothesize that the function of 
the Wnt signaling pathway can change during different phases of prostate 
maturation. 
 Prostate development is controlled by androgens, but estrogen and 
estrogenic endocrine disruptors have shown a variety of effects on prostate 
growth and branching prostate [78]. By using an inducible system for gene 
deletion that requires the presence of tamoxifen, a partial agonist of the estrogen 
receptor in mice, we were compelled to carefully control for potential effects of 
tamoxifen on prostate lineage specification and branching.  Fortunately, no 
observable effects of tamoxifen on UGS organ culture were noted, even at one 
log higher concentration than those necessary to induce Cre recombination.  
Androgen induced signals from the UGM to the UGE initiate prostate 
development [31].  So called “andromedins” are postulated to relay this signal 
and induce prostatic differentiation.  A number of Wnt family members are 
expressed in the UGS in a manner consistent with a role in epithelial-
mesenchymal interactions during prostate induction, and could function as 
andromedins [35, 36, 38]. Here we show that canonical Wnt signaling in the 
epithelium is induced after androgen exposure.  Although we have determined 
that canonical Wnt signaling is required for prostate specification, the source and 
identity of the initiating Wnt ligand has yet to be determined.  Because this 
inducible system deletes beta-catenin in both the epithelium and mesenchyme, 
we could not determine which compartment requires Wnt signaling.  Although 
Nkx3.1-Cre expression is specific to the epithelium, the ability of prostatic 
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differentiation to occur after Nkx3.1-Cre mediated deletion of beta-catenin 
suggests that either the Wnt requirement is mesenchymal, or, as we hypothesize, 
that the requirement is epithelial, but transient, and abates prior to Nkx3.1-Cre 
expression. While it remains unclear whether UGE or UGM initiates Wnt 
signaling, we detect androgen induced Wnt signaling exclusively in the UGE. 
An additional aspect of this pathway which remains undetermined is the 
precise role of Wnt/beta-catenin signaling in prostate lineage commitment, and 
the downstream mediators that carry out this role.  In our study, the absence of 
identifiable prostatic structures in beta-catenin null tissue indicates an absolute 
requirement for this protein in prostatic induction.  However, it is unclear if Wnt 
signaling is directly inducing prostatic lineage committment, or if it plays 
another, more permissive role, such as promoting survival or proliferation of 
committed prostate progenitors.  A key to determining the function of Wnt 
signaling will be determining the downstream targets which are subsequently 
induced.  Previous studies have indicated that Foxa2 is positively regulated by 
activated Wnt signaling [43, 68].  Here we show the complement, that Foxa2 
expression is diminished after beta-catenin deletion.  The timing and localization 
of Foxa2 during prostate development, expression only during early 
morphogenesis, suggest it may play a role in the earliest stages of prostate 
lineage commitment.  Our data confirm that Foxa2 is regulated by Wnt signaling, 
suggesting a potential pathway which could mediate the transient requirement 
for Wnt signaling in prostate development. 
In summary, we show a critical requirement for canonical Wnt/beta-
catenin signaling in early prostate lineage commitment.  To accomplish this, we 
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adapted a strategy for gene deletion to use in studies of prostatic differentiation 
and development that allows careful interrogation of gene function at the earliest 
stages of prostate development.  Future studies should focus on the identity and 
source of the signaling molecules that initiate Wnt signaling in the UGE, and 
what downstream targets mediate this effect.  
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Figure 1:  Androgen induces Wnt signaling in UGE during prostate specification.  (A) 
qRT-PCR of male and female E16.5 separated UGE and UGM for Axin2 
expression normalized to respective female samples.  Differential expression of 
Axin2 was limited to the UGE (p<0.01). (B) E15.5 female UGSs cultured in vitro 
with DHT demonstrated a significant increase in Axin2 expression at 24 and 48 
hours (p<0.01) by qRT-PCR of separated UGE, coinciding with significant 
increases in Nkx3.1 expression (p<0.01).  Graphs represent mean ± standard error 
of the mean (SEM), p-values calculated using unpaired two-tailed Student’s t-test 
















































Figure 2:  Inducible knockout of beta-catenin is rapid and results in decreased Foxa2 
expression.  (A) Immunoblot analysis of E15.5 CreERT1 Ctnnbfl/fl UGSs grown in 
vitro with 2 mM tamoxifen showed decreased beta-catenin protein level after 24 
hours and loss within 48 hours.  (B)  H&E stain and IHC confirmation of beta-
catenin deletion after 48 hours tamoxifen treatment (scale bar 100 micrometers).  
Nkx3.1 expression is undetectable, and FoxA2 expression is limited to scattered 
individual cells (arrows and inset). AR expression was similar between the two 
groups. Scale bars are 100 micrometers. (C) qRT-PCR analysis of whole UGSs 
after 48 hour tamoxifen treatment demonstrates decreased beta-catenin (Ctnnb1), 
Axin2, Tcf7, and Foxa2 expression relative to vehicle treated controls (p<0.01).  
Graph represents mean ± standard error of the mean (SEM), p-values calculated 
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Figure 3:  Deletion of beta-catenin prevents prostate differentiation and bud formation in 
vitro.  (A) Wildtype (left column) and CreERT1 Ctnnb1fl/fl (right column) E15.5 
UGSs cultured in vitro for five days with 2 mM tamoxifen, vehicle, or 20nM 
PKF118-310.  (B) Quantitative analysis of bud formation in vitro demonstrates 
significantly reduced bud formation in beta-catenin deleted and inhibitor treated 
tissues compared to controls (n=5, p<0.01), but no difference in tamoxifen-treated 
versus vehicle treated wildtype UGSs (n=5, p=0.663).  Graph represents mean ± 
standard error of the mean (SEM), p-values calculated using unpaired two-tailed 
























































Figure 4:  Beta-catenin knockout grafts do not show prostatic differentiation.  Renal 
grafts from E15.5 CreERT1 Ctnnb1fl/fl UGSs grown after 48 hour in vitro culture with 
vehicle (A-G) or tamoxifen (H-N) before 4 weeks growth as subcapsular renal 
grafts.   Vehicle treated grafts show normal prostate gland formation (B, C), and 
express beta-catenin (D), Nkx3.1 (E), Hoxb13 (F), and AR (G).  Beta-catenin 
deletion resulted in smaller grafts compared to controls (A, H), and H&E 
staining demonstrates disorganized grafts without recognizable prostatic 
differentiation (I, J).  IHC analysis showed loss of beta-catenin (K), and Nkx3.1 
(L).  Hoxb13 expression was absent in the majority of tissue (M), with expression 
limited to small foci of cells with periurethral gland differentiation (inset).  
Grafted tissue retains AR expression (N).  Scale bars 500 micrometers in B, I.  All 
others 50 micrometers. 
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Figure 5:  Beta-catenin deletion after differentiation does not prevent bud formation.  
Organ cultures of E15.5 Nkx3.1-Cre Ctnnb1fl/+ and Ctnnb1fl/fl UGSs show normal 
beta-catenin (A) and Nkx3.1 (C) expression in control UGS prostate buds after 5 
days in controls.  Nkx3.1-Cre Ctnnb1 fl/fl mice form (B) beta-catenin deficient 
prostate buds that (D) maintain Nkx3.1 expression. Scale bars are 50 
micrometers. 















Figure 6:  After androgen action, prostate glands can form without beta-catenin.  Grafts 
from P0 CreERT1 Ctnnb1fl/fl prostates treated in vitro with vehicle (A-D) or 
tamoxifen (E-H) for 48 hours show normal development in controls (A-D).  
Tamoxifen treated grafts are smaller than controls, but show prostate gland 
formation (E,F) despite loss of beta-catenin (G), and retain Nkx3.1 expression (H).  
Grafts from E15.5 female UGSs pretreated with DHT for 24 hours before 
exposure to tamoxifen (I-L) show a small number of prostate glands (I, J) forming 
without beta-catenin (K) that retain Nkx3.1 expression (L).  (M) Timeline 
depicting normal prostatic differentiation, bud formation, and the transient 
requirement for Wnt signaling on which these processes rely. Scale bars 500 
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Figure 7:  Mature secretory luminal cells maintain prostatic identity after beta-catenin 
deletion.  Pb-Cre4 Ctnnb1fl/fl mice show mosaic deletion of beta-catenin in luminal 
prostate epithelial cells.  In areas with beta-catenin expression (arrow) and in 
areas of beta-catenin deletion (arrowhead) epithelial cells retain normal 
expression and localization of E-cadherin (A) and Androgen receptor (B) by 
immunofluorescence.  (C,D) Two color immunohistochemistry shows mosaic 
beta-catenin expression (purple) and normal expression of   Hoxb13 (C), and 





























Figure S1:  Tamoxifen does not inhibit bud formation in vitro.  UGSs from E15.5 
female embryos cultured for 5 days with vehicle or 20 mM tamoxifen formed 
similar numbers of buds. 








Figure S2:  Grafts from beta-catenin deleted UGSs are significantly smaller than 
controls.  Quantitative analysis of graft weights from E15.5 CreERT1 Ctnnb1fl/fl UGSs 
cultured in vitro for 48 hours with tamoxifen before grafting weighed 
significantly less than vehicle treated controls (n=8-12, p<0.0001).  Graph 
represents mean ± standard error of the mean (SEM), p-values calculated using 
























Figure S3:  Differentiation of beta-catenin deleted UGSs.  Wildtype adult seminal 
vesicle stains strongly with anti-SV antibody (A), while prostate glands from 
E15.5 CreERT1 Ctnnb1fl/fl UGSs cultured in vitro for 48 hours with vehicle before 
grafting are not SV positive (B).  Tamoxifen treated grafts do not contain SV 
positive epithelium (C).  Grafts from tamoxifen-treated, beta-catenin deleted 
UGSs were small and composed primarily non-prostatic tissues derived from, or 
adjacent to, the UGS such as:   (D) urothelium (arrowhead), (E) periurethral 
glands, (F) ampullary glands with characteristic stroma (arrow) and “swiss 
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Figure S4:  Androgen exposure reduces the requirement for beta-catenin in bud 
formation.  Male or female E15.5 CreERT Ctnnb1fl/fl UGSs cultured with vehicle for 
5 days show normal bud numbers (top row), but tamoxifen treatment to delete 
beta-catenin results in lack of bud formation (middle row).  Pretreatment of 
female E15.5 UGSs for 24 hours with DHT before tamoxifen exposure, or in vivo 
exposure to testicular antigens of E16.5 males allows partial bud formation 
(bottom row) after 5 days in culture. 
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Figure S5:  Cellular differentiation in beta-catenin null glands. Grafts from P0 CreERT1 
Ctnnb1fl/fl UGSs prostates treated in vitro with vehicle (A-E) or tamoxifen (F-J) 
show normal expression and localization of (A) beta-catenin, (B) SMA, (C) p63, 
(D) CK14, and(E) CK8.  Tamoxifen treated grafts (F-J) show loss of (F) beta-
catenin, and (G) occasional incomplete smooth muscle capsules (arrow).  (H) p63, 
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Inflammation is associated with several diseases of the prostate including benign 
enlargement and cancer, but a causal relationship has not been established. Our 
objective was to characterize the prostate inflammatory microenvironment after 
infection with a human prostate derived bacterial strain and to determine the 
effect of inflammation on prostate cancer progression. To this end, we mimicked 
typical human prostate infection with retrograde urethral instillation of CP1, a 
human prostatic isolate of Escherichia coli. CP1 bacteria were tropic for the 
accessory sex glands and induced acute inflammation in the prostate and 
seminal vesicles with chronic inflammation lasting at least one year. Compared 
to controls, infection induced both acute and chronic inflammation with 
epithelial hyperplasia, stromal hyperplasia, and inflammatory cell infiltrates. In 
areas of inflammation, epithelial proliferation and hyperplasia often persist 
despite decreased expression of androgen receptor (AR). Inflammatory cells in 
the prostates of CP1 infected mice were characterized at 8 weeks post-infection 
by flow cytometry, which showed an increase in macrophages and lymphocytes, 
particularly Th17 cells. Inflammation was additionally assessed in the context of 
carcinogenesis. Multiplex cytokine profiles of inflamed prostates showed distinct 
inflammatory cytokines were expressed during prostate inflammation and 
cancer, with a subset of cytokines synergistically increased during concurrent 
inflammation and cancer. Furthermore, CP1 infection in the Hi-Myc mouse 
model of prostate cancer accelerated the development of invasive prostate 
adenocarcinoma with 70% more mice developing cancer by 4.5 months of age. 
This study provides the first direct evidence that prostate inflammation 
accelerates prostate cancer progression, and gives insight into the 
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microenvironment changes induced by inflammation that may accelerate tumour 
initiation or progression.  
 




Chronic inflammation is associated with increased cancer risk in a number of 
organs, including stomach, pancreas, colon, and lung [79]. A variety of 
epidemiologic and histopathologic evidence suggests prostate cancer risk also 
correlates with inflammation, but a causal relationship has been difficult to 
establish in human studies [12, 80-83]. One factor contributing to this difficulty is 
the high prevalence of clinically silent prostatitis. More than 77% of men have 
histologic evidence of prostate inflammation, but less than 10% of these men 
report symptoms of prostatitis [84]. A second confounding issue is detection bias. 
Men with symptomatic prostatitis are more likely to be diagnosed with prostate 
cancer because they are more likely to be treated by a urologist and subsequently 
screened for cancer [83]. These difficulties have driven an increased focus on 
animal models of prostate inflammation and prostate cancer [12]. 
Despite the high prevalence of prostatitis, the cause of this disease remains 
uncertain in most cases. Many factors have been proposed as the initiating cause 
of prostate inflammation, including viruses, bacteria, hormones, urinary reflux, 
and diet [12]. Bacteria can be isolated from only a minority of cases of prostatitis, 
but when a bacterial species can be cultured from prostatic secretions, the 
majority of these are Escherichia coli [85]. Numerous studies using non-culture 
based techniques have confirmed the presence of E. coli in additional cases of 
prostatitis by detecting bacterial DNA in inflamed prostates and in corpora 
amylacea [86-88]. Together, these data indicate that prostate infection by E. coli is 
an important, and potentially underreported, cause of chronic prostatitis. 
 Inflammation alters the prostatic microenvironment in multiple ways that 
may facilitate cancer initiation or progression [12]. Infiltrating leukocytes secrete 
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a variety of cytokines that promote prostate epithelial proliferation [89]. Release 
of reactive oxygen and nitrogen species can directly damage DNA [90]. Other 
inflammatory cells, especially macrophages, migrate through the stroma and can 
secrete proteolytic enzymes that degrade the extracellular matrix and may 
facilitate invasion or metastasis [91]. A variety of inflammatory cell types have 
been identified in human Proliferative Inflammatory Atrophy (PIA) and prostate 
cancer, and have been proposed to mediate many of these changes in the 
microenvironment. Among these are macrophages and T cells, particularly IL-17 
secreting Th17 cells [92-94]. When tested in animal models of prostate and colon 
cancer, these cell types were found to promote carcinogenesis or tumour 
progression via STAT3 activation [92, 95]. Thus, multiple mechanisms have been 
postulated to promote cancer initiation or progression due to chronic prostatitis, 
but the relative contribution of each has not been established. 
 Animal models have been used to study prostatitis with a variety of 
methods to induce inflammation, including bacteria, hormone treatment, and 
immunization [17, 26, 27, 96]. Although previous reports describe reactive 
inflammatory changes and pre-invasive mouse prostatic intraepithelial neoplasia 
(mPIN) in mice with chronic prostatitis, the effect of prostatic inflammation on 
prostate cancer progression is unknown [27, 96-99]. We chose to use a recently 
developed model of bacterial prostatitis using the E. coli isolate CP1. This strain 
of bacteria differs from other reported bacterial models in that it was isolated 
from the prostate of a human, and has been shown to induce chronic prostatitis 
in a several mouse strains [100]. Previous analysis of prostatitis induced by CP1 
demonstrated tropism for the prostate and induction of persistent inflammation 
in C57BL/6J mice despite the absence of detectable bacteria by culture after 28 
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days [100]. Because inflammation has been associated with multiple human 
prostatic diseases, we first characterized the long-term effects of inflammation 
from a human bacterial isolate on the prostatic epithelium and stroma. 
Additionally, as chronic inflammation has been linked to multiple cancers, 
including prostate cancer, we explored the influence of infection-associated 
inflammation on cancer progression in the Hi-Myc model of prostate cancer 
[101]. Here we show CP1 induces chronic inflammation characterized by an 
influx of macrophages and Th17 lymphocytes, and accelerates cancer 
progression in Hi-Myc mice.  Additionally, we demonstrate distinct cytokine 
profiles induced by inflammation and cancer.  
 
Materials and Methods 
Mice 
All experimental procedures were approved by the Johns Hopkins Institutional 
Animal Care and Use Committee (IACUC). Wild type C57BL/6J and FVB/NJ 
were obtained from Jackson Laboratories (Bar Harbor, ME, Stocks 664 and 1800). 
FVB-Tg(ARR2/Pbsn-MYC)7Key (Hi-Myc, Strain 01XF5) mice were obtained 
from NCI Mouse Repository (Frederick, MD). Genotyping was performed using 
primer sets and protocols recommended by the vendor.  Genomic DNA for PCR 
was isolated from tails. 
 
Bacterial Strain and Intraurethral Inoculation 
CP1 is an E. coli strain of the B1 clonal group isolated from the expressed 
prostatic secretion (EPS) of a patient with chronic prostatitis [100]. Bacterial 
culture and transurethral inoculation were performed as previously described 
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[100, 102]. To infect mice, 10 mL of phosphate-buffered saline containing 1 x 108 
cfu CP1 bacteria was introduced into the urethra of anesthetized mice by 
catheterization. Sterile saline was introduced in control animals in an identical 
fashion. All mice were inoculated with a single dose of CP1 at 8 weeks of age. 
Heat-killed bacteria were heated at 70oC for 30 minutes. Culture supernatant was 
prepared by centrifugation followed by 0.2 µm filtration. Lack of viable cells was 
confirmed for heat-killed bacteria and supernatant by zero colony growth on 
agar plates.  
 
Histology and Immunohistochemistry 
At indicated times, prostates were harvested and dissected to separate lobes, 
fixed in formalin, processed, embedded, sectioned and stained with hematoxylin 
and eosin (H&E). Inflammation and cancer were scored according to established 
guidelines in a blinded fashion [103]. For immunohistochemistry, slides were 
deparaffinised and rehydrated before steaming in Target Retrieval Solution 
(Dako), or EDTA pH8 (Invitrogen) for 40 minutes. Endogenous peroxidases were 
quenched with BLOXALL (Vector Labs), and the slides were blocked for one 
hour with Serum Free Protein Block (Dako). Slides were incubated with 
antibodies directed against CK8 (Covance), CK14 (Covance), p63 (Sigma), F4/80 
(Abcam), CD3 (Abcam), SMA (Dako), Ki67 (Abcam), Phosphorylated STAT3 
(Cell Signaling), Myc (Abcam), Laminin (Sigma), AR (Santa Cruz, N-20), 
Vimentin (Cell Signaling) and Nkx3.1 [61]. Staining was visualized with 




To obtain prostate-infiltrating lymphocytes, prostate tissue was mechanically 
disrupted and incubated for 1 hour at 37°C in RPMI Media with Liberase DL 
(Roche Applied Science) following manufacturer’s instructions. Lymphocytes 
were isolated using Ficoll-Paque Premium gradient centrifugation (GE 
Healthcare). For intracellular cytokines, lymphocytes were stimulated for 6 hours 
with PMA (100 ng/mL), ionomycin (500 ng/mL), and Golgi-stop (BD 
Biosciences) at 37°C.   Intracellular staining was performed with the Ebioscience 
permeabilization buffer. The cells were analyzed by fluorescence activated cell 
sorting (FACS) analysis using a FACSCalibur flow cytometer (BD Biosciences). 
All antibodies were purchased from BD Bioscience except anti-FoxP3 
(eBioscience). Data were analyzed with FlowJo software (Treestar Inc.). 
 
Cytokine Assay 
Tissues from saline treated C57BL/6J, saline treated FVBN/J, CP1 treated 
C57BL/6J, saline treated Hi-Myc, and CP1 treated Hi-Myc were harvested at 6 
months of age (4 months post-inoculation). The prostate was frozen and stored at 
-80oC until the assay. Frozen tissue samples were homogenized 
in homogenization buffer (50 mM Tris-HCl, pH 7.2) containing Na3VO4 and a 
protease-inhibitor cocktail (Sigma-Aldrich) using an OmniTH homogenizer 
(Omni International, Marietta, GA). Following sonication, the homogenate was 
centrifuged at 2000g for 5 minutes. The resulting supernatants were collected as 
total prostate proteins and protein concentrations were measured using the Bio-
Rad Protein Assay (Hercules, CA). To quantify cytokine levels, a multiplex 
mouse 20-plex cytokine immunoassay (Life Technologies), was used. Analytes 
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measured include GM-CSF, IFN-g, IL-1a, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, 
IL-13, IL-17, TNF-α, CCL2, CCL3, CXCL1, CXCL9, and CXCL10. Prostate protein 
samples were run in duplicate as previously described [104]. Analyte 
concentrations were quantified by fitting using a standard curve and normalized 
by total protein concentration. 
 
Statistical Analysis 
All experiments were performed using five or more mice in independent 
experiments. For comparisons between two groups, Student’s t test was used. 
For multiple comparisons, One-way ANOVA with Tukey’s multiple 
comparisons test was used (Graphpad Prism). 
 
Results 
CP1 induces chronic prostatitis with stromal and epithelial hyperplasia 
 We first sought to determine the duration and distribution of prostatitis 
that could be initiated by a single intraurethral exposure to CP1 bacteria. At 8 
weeks of age, wild type C57BL/6J mice were inoculated with CP1 or sterile 
saline. Bacteria were delivered via catheter into the proximal urethra (Fig. S1). 
Prostate tissue was harvested 8 weeks, 6 months, and 1 year after inoculation and 
processed for histology. No inflammation above expected background was noted 
in saline treated control mice at any time point (Fig. 1A&E). CP1 consistently 
produced chronic prostatitis, with inflammation present in 89% (34/38) of mice 
at 8 weeks, 85% (17/20) of mice at 6 months and 40% (4/10) of mice after 1 year. 
After 8 weeks, mixed inflammatory cells multifocally infiltrated prostate stroma 
and glands, with reactive epithelial hyperplasia in inflamed glands (Fig. 1B&F) 
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characterized by multiple layers of epithelial cells, tufting, and cribriform 
changes. At later time points, inflammatory cells were still present, but glands 
were often lined by attenuated epithelium with more prominent stromal 
hyperplasia (Fig. 1C-D&G-H). Inflammation was most common in the anterior 
prostate, but was common in all lobes (Fig. 1I). The majority of mice (71%, 27/38) 
had inflammation present in two or more lobes after 8 weeks (Fig. 1J); however, 
inflammation was not uniformly distributed with inflamed and normal glands 
present in all mice. Viable intact bacteria are required during the initial 
inoculation to produce this sustained inflammatory response, as neither heat-
killed bacteria nor filtered culture supernatant produced any inflammation (Fig. 
S2). 
Consistent with previous reports of other models of chronic prostatitis, CP1 
inflammation induces reactive hyperplasia in both basal and luminal 
compartments [27, 97]. Basal cells, marked by immunohistochemical staining for 
cytokeratin 14 (CK14) or p63, increased from a single, incomplete layer in control 
mice to a layer often two to three cells thick in areas of inflammation (Fig. 2A-D). 
Similarly, the luminal cell layer, marked by cytokeratin 8 (CK8) was thickened in 
inflamed areas (Fig. 2E&F). In addition to epithelial hyperplasia, marked stromal 
thickening was noted in inflamed glands, especially at later time points (Fig. 1 C-
D).  Prostate glands in saline treated controls were surrounded by a thin layer of 
smooth muscle (Fig. 2K), with minimal collagen and few vimentin positive 
stromal cells (Fig S3).  Inflamed glands showed a disruption of the smooth 
muscle actin (SMA) positive stromal layer (Fig. 2L). The inflamed stroma was 
thickened by bands of collagen, indicated by blue staining with Masson’s 
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trichrome histochemical stain, and vimentin positive reactive stromal cells (Fig. 
S3). 
In addition to hyperplastic changes, inoculation of CP1 induced infiltration of 
numerous immune cells.  Immunohistochemical analysis of inflamed prostates 
for the macrophage marker F4/80 showed marked infiltration of the stroma and 
glands 8 weeks post-infection (Fig. 2 G&H). Similarly, CD3+ T cells were present 
throughout inflamed areas of the prostates while rare in controls (Fig. 2 I&J). To 
further characterize the inflammatory infiltrate, dissociated prostates from wild 
type mice were analysed by flow cytometry 8 weeks post-infection to quantify 
inflammatory cells. The absolute number of lymphocytes and macrophages was 
significantly increased at this time point (Fig. 3A-C). The relative populations of 
T cells (including CD4+, CD8+, gd+) and their respective subtypes (IFN-g+ or IL-
17+), CD4+ FoxP3+ cells (Treg), and CD49b+ cells (includes NK cells) were 
quantified. Significant increases in the relative proportion of gd T cells and CD4+ 
IL-17+ (Th17) cells were noted in inflamed prostates compared to saline treated 
controls (Fig. 3). 
 
Chronic prostatitis promotes prostate cancer progression 
CP1 inoculation produces marked epithelial and stromal hyperplasia with 
moderate atypia and occasional cribriform morphology that resembles mPIN, 
but no definitive foci of invasive cancer were identified at any time point. This 
indicates that CP1 infection alone is insufficient to initiate invasive cancer 
formation in wild type C57BL/6J mice. However, upregulation of multiple 
oncogenes and pro-oncogenic pathways suggested that CP1 induced 
inflammation could affect prostate cancer progression. Epithelial proliferation, 
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determined by immunohistochemical staining for Ki67, was dramatically 
increased at 8 weeks post-infection and remained elevated one year post-
infection (Fig. 4A, E, I). Quantification of percent Ki67 positive epithelial cells 
showed a significant increase at 8 weeks (9.3±1.8%, p<0.001) and one year 
(10.9±3.2%, p<0.001) compared to controls (0.5±0.3%). In addition to increased 
proliferation, inflamed prostates showed widespread expression of MYC and 
activation of STAT3 (Fig. 4), both oncogenes shown to promote prostate cancer 
initiation or progression in mice and humans [101, 105-107]. Finally, 
inflammation induced fragmentation of the normally continuous prostate 
basement membrane, which could facilitate cancer invasion (Fig. 4D, H, L).  
Similar to previous reports, AR expression and the AR target NKX3.1 are 
diminished in areas of inflammation (Fig. 5) [27]. Luminal cells typically express 
high levels of nuclear AR and NKX3.1 (Fig. 5A&E).  In castrated mice, AR levels 
decrease and nuclear localization is lost, with subsequent decrease in androgen 
dependent genes, such as Nkx3.1 (Fig. 5 B&F).  In inflamed prostate glands, AR 
and Nkx3.1 expression are diminished (Fig. 5 C&G), but the epithelial cells 
remain highly proliferative (Fig. 5 D&H). 
Because CP1-induced inflammation induces pro-oncogenic epithelial changes, 
we investigated its role in prostate cancer progression. We inoculated Hi-Myc 
mice with CP1 or sterile saline at 8 weeks of age. In this model of prostate cancer, 
mPIN develops at an early age and progresses to invasive cancer by 6 months of 
age in 100% of animals [108]. At 4.5 months of age (137±2 days), a minority of 
saline treated mice had foci of invasive cancer (43%, N=26/60). However, 
significantly more CP1 treated mice had invasive cancer (73%, N=22/30, 
p=0.008). Similar to wild type mice, Hi-Myc mice showed little expression of 
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phosphorylated STAT3 throughout tumourigenesis. In contrast, phosphorylated 
STAT3 expression was widespread in inflamed areas of CP1 treated Hi-Myc mice 
(Fig.6). 
 
Inflammation and cancer have distinct cytokine profiles 
The high incidence of both prostate inflammation and prostate cancer in humans 
makes it difficult to determine the individual effect of each on cytokine 
expression and immune cell infiltrates [93]. However, these processes can be 
separated in mouse models. We employed multiplex assays to compare cytokine 
levels in saline treated wild type mice, CP1 inoculated wild type mice, saline 
treated Hi-Myc mice, and CP1 inoculated Hi-Myc mice all at 6 months of age (4 
months post infection, Fig. 7). Of the twenty cytokines and chemokines included 
in the multiplex ELISA, seventeen had significantly different expression levels 
among treatment groups. These cytokines could be separated into distinct 
profiles of those associated specifically with inflammation, with cancer, or only 
when inflammation and cancer were present concurrently (Table 1). Cytokines 
were considered to be associated with inflammation when expression levels were 
significantly increased in CP1 treated animals when compared to wild type and 
cancer groups. Cytokines were considered to be associated with cancer when 
expression levels were significantly increased in Hi-Myc mice compared to wild 
type and CP1 treated wild type mice.  
 
Discussion 
Inflammation contributes to cancer initiation and progression in a variety of 
organs, and has been shown to act directly by inducing genetic changes and 
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indirectly by altering the microenvironment through immune cell infiltrate and 
cytokine expression. Here, we show the first evidence that prostate inflammation 
accelerates prostate cancer progression and examine the complex inflammatory 
infiltrate and cytokine milieu associated with inflammation in the prostate 
glandular microenvironment.  
 
CP1 Model of Prostatitis 
In this report, we utilize the CP1 model of prostatitis, which has proven useful 
for investigations into mechanisms of prostatitis, chronic pelvic pain, and now 
prostate cancer. We feel this model has several distinct advantages. CP1 was 
isolated from prostatic secretions, and thus may more closely model typical 
human infectious prostatitis. Additionally, some infectious models of prostatitis 
require direct injection into the prostate, or project bacteria into prostate ducts by 
larger volume urethral inoculation. CP1 colonizes the mouse prostate after 
infusion of a very small volume inoculate into the urethra, thus eliminating the 
confounding inflammation related to urine reflux or distension of prostate ducts. 
We show that CP1 is capable of inducing inflammation that persists at least one 
year after a single infusion of bacteria and clearance of the bacteria within 28 
days of inoculation [100]. It is not clear if the ability to promote cancer 
progression is a unique feature of CP1, or if this is a feature of inflammation in 
general. This will be possible by comparing CP1 induced acceleration of prostate 





Inflammation induced by CP1 recruits a variety of inflammatory cells, especially 
macrophages and lymphocytes, to the prostate. One component is a strong Th17 
response, indicated both by an increase in CD4+ IL-17+ cells and by an increase 
in IL-17 production during CP1 induced inflammation. This finding is consistent 
with previous reports of a strong Th17 response to bacteria [95, 109]. However, 
not all inflammatory models of prostatitis evoke a Th17 response, and the 
intensity of Th17 response has been shown to be dependent on mouse strain and 
can vary based on environmental factors [110, 111]. We hypothesize that 
accelerated cancer progression in CP1 infected mice is, at least in part, due to 
activation of the IL-17/IL-6/STAT3 pathway, as this pathway is critical for 
cancer progression cancer in other organs, and IL-17 has been shown to promote 
prostate cancer progression in mice [95, 112, 113]. Although our investigation 
focused on immune cell subtypes and cytokine expression during inflammation 
and cancer, one histologic hallmark of cancer is invasion through the basement 
membrane. Stromal remodelling and disruption of basement membrane, which 
occurs during inflammation, may provide a purely mechanical advantage for 
pre-invasive lesions to progress towards malignancy.   
 
Cytokine Profiles of Inflammation and Cancer 
Although we anticipated different cytokine expression profiles for infection and 
cancer, the distinct profile of coincident inflammation and cancer was surprising. 
This profile may be due to an increase in intensity of inflammation from the dual 
stimuli of bacterial infection and cancer, or from synergistic interactions of anti-
bacterial and anti-tumour inflammation. Cytokine levels during simultaneous 
inflammation and cancer were higher than either state alone for 11/20 cytokines 
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tested. This increase in inflammatory intensity may activate cytokine expression 
not present in either state alone. For example, IL-17 is significantly increased 
during inflammation, but concurrent inflammation and cancer caused an 8-fold 
increase in mean IL-17 expression compared to inflammation alone. IL-6 
expression can be induced by IL-17 activity, and the dramatic increase in IL-17 
during simultaneous inflammation and cancer may explain the upregulation of 
IL-6 only in this environment [112]. An alternate explanation for the distinct 
profiles is that the immune response to infection and cancer initiation are 
different, and the combination of the two invokes a third distinct immune 
microenvironment. Inflammation in response to bacterial exposure produces 
significant tissue damage from reactive oxygen species produced by 
macrophages and neutrophils. When coupled with immune response to tumour 
formation, this may result in a different immune phenotype than either process 
alone. 
If confirmed in human studies, these distinct cytokine profiles could provide a 
useful diagnostic tool to segregate inflammation and cancer. Although it is more 
difficult to separate the influence of inflammation from cancer on cytokine 
expression in humans, we see some correlation between our data and published 
cytokine data in human studies. For example, TNFa and IL-1a were previously 
found to be upregulated in men with Chronic Prostatitis or Chronic Pelvic Pain 
Syndrome [114]. We have identified a cytokine profile specific for murine 
prostate cancer (IL-5, IL-13, CCL2) that may be useful when translated to the 
human setting. This profile is traditionally associated more with allergic disease 
than cancer, but IL-13 and CCL2 have been shown to promote prostate cancer 
cell proliferation and migration [115-117]. Interestingly, the cytokine profiles of 
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CP1-induced inflammation and cancer were mutually exclusive, i.e. no cytokine 
was elevated compared to controls in both settings. Although significant 
immune cell infiltrate is present in Hi-Myc mice with cancer and in mice treated 
with CP1, this confirms that the microenvironments of the two processes are 
quite distinct. 
 
Increased Proliferation Despite Decreased Androgen Receptor Expression 
Several groups have reported a decrease in AR expression during inflammation 
[26, 27, 118]. Here, we show inflammation induces increased proliferation in 
luminal epithelial cells despite diminished AR expression. As this phenotype 
appears rapidly after the induction of inflammation, it suggests an inherent 
program for proliferation in luminal cells in an AR diminished setting without 
evolution of androgen independent clones through mutation. AR has been 
proposed to function as a growth suppressor in mature luminal cells, and its loss 
in the context of inflammation may permit the epithelium to respond to 
proliferative signals from the stroma [119]. The mechanism driving this program 
is unclear from this study, but understanding this process could uncover 
mechanisms of other AR independent processes in the prostate, such as 
castration resistant prostate cancer.   
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Figure 1:  CP1 induces chronic prostatitis.  Representative images of prostate 
glands after control saline treatment (A&E), or CP1 induced inflammation at 8 
weeks (B&F), 6 months (C&G), and 1 year (D&H) after infection show sustained 
inflammation. (I) Distribution of inflammation by individual lobe (N=38) 
DL=dorsal, AP=anterior, LP=lateral, VP=ventral. (J) Total number of inflamed 
























Figure 2:  CP1 infected prostates are hyperplastic and infiltrated by immune cells.  
Representative images of immunohistochemistry comparing saline treated 
controls and CP1 infected prostates 8 weeks after infection demonstrates 
hyperplasia of basal cells (CK14, A&B; p63 C&D), luminal cells (CK8, E&F), and 
thickened stroma with disruption of the smooth muscle actin positive layers 
(SMA, K&L). Inflamed prostates show increased infiltration of macrophages 
(F4/80, G&H), and T cells (CD3, I&J). Scale bar = 50 micrometers. 


























Figure 3:  Prostate inflammatory phenotype. Analysis of prostate infiltrating 
immune cells by flow cytometry comparing saline treated controls and CP1 
infected wildtype prostates 8 weeks after infection. Significant differences 
(P<0.05) were noted in total lymphocyte number, macrophage number, total 
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Figure 4:  CP1 inflamed epithelium adopts a proliferative and pro-oncogenic phenotype.  
Immunohistochemistry demonstrates increased proliferation (Ki67, A, E, I), 
phosphorylated-STAT3 (B, F, J) and c-MYC (C, G, K) expression, and disrupted 
laminin (D, H, L) by CP1 infected mice after 8 weeks (E-H) and 1 year (I-L) 
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Figure 5:  Diminished AR expression and signaling in inflamed epithelium.  
Immunohistochemistry for AR (A-D) and NKX3.1 (E-G), an androgen regulated 
protein, shows strong nuclear expression in normal glands (A&E), but 
significantly decreased expression of both proteins two weeks after castration 
(B&F).  Expression of both proteins is decreased to castrate levels in inflamed 
epithelium 8 weeks post inoculation (C&G).  Despite decreased AR expression, 
inflamed epithelium remains highly proliferative with numerous Ki67 positive 
nuclei (D&H). 
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Figure 6: CP1 infection accelerates cancer progression. Representative images of 
prostates from 4.5 month old Hi-Myc mice treated with saline (A&D) or CP1 (B, 
C, E). Immunohistochemistry for phosphorylated-STAT3 (D&E) shows activation 
in CP1 treated, but not saline treated controls. At 4.5 months of age (F), 
significantly more mice have invasive carcinoma in CP1 treated group compared 
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Figure 7:  Cytokine expression during inflammation and cancer.  Multiplex cytokine 
profiles of whole prostate lysates from 6-month-old (4 months post-inoculation) 
saline treated wildtype mice (Saline), saline treated Hi-Myc mice (Cancer), CP1 
treated wildtype mice (Inflamed), and CP1 treated Hi-Myc Mice (Infl+Cancer). 
Box plots show median and min/max values of 10 mice for saline treated 






































































































































































































































































































Table 1:  Inflammation and cancer have distinct cytokine profiles.  Cytokines can be 
grouped according to expression profile. Cytokines associated with 
inflammation are significantly increased in inflamed prostates, regardless of 
cancer status. Cytokines associated with cancer are significantly increased in 
cancer, regardless of inflammation status. Concurrent inflammation and cancer 
cytokines are significantly increased only when inflammation and cancer are 
simultaneous. 
Cytokines Associated with 
!
Cytokines Associated with 
Cancer!
Only Induced by 
Concurrent 
 and 
Cancer!Only Induced by ! !





   IL-1α     IL-2!




     CXCL10!
IL-4     CXCL1!
IL-6     CXCL9   !
IL-12   IFNγ"
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Figure S1:  Catheter placement.  Dye injected into the urethra in an identical 
manner to CP1 or saline treatment stains the bladder and proximal urethra, but 





Figure S2:  Live bacteria are required to induce inflammation.  Representative 
histology of prostate glands two weeks after instillation of heat-killed CP1 
culture (A, B) or filtered culture supernatant (C, D) show no inflammatory 






Figure S3:  Inflammation induces reactive stromal hyperplasia.  Masson’s trichrome 
stain (A-D) and immunohistochemistry for vimentin (E-H) show thickened 
stroma with increasing collagen deposition (blue color) and numerous vimentin-
positive stromal cells in inflamed glands at 8 weeks, 6 months, and 1 year after 
infection compared to saline treated controls. 











A! B! C! D!
E! F! G! H!
 78 
IV. References 
1. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, 
Beer TM, Bauer DC, Zmuda JM, Orwoll ES, and Osteoporotic Fractures in 
Men Study Research G, Prevalence, severity, and health correlates of lower 
urinary tract symptoms among older men: the MrOS study. Urology, 2006. 
68(4): p. 804-9. 
2. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, 
Lundberg S, Sparke B, Sternby NH, and Tulinius H, Latent carcinoma of 
prostate at autopsy in seven areas. The International Agency for Research on 
Cancer, Lyons, France. Int J Cancer, 1977. 20(5): p. 680-8. 
3. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, 
Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin 
AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, 
Montie JE, Xu J, Carpten JD, Isaacs WB, and Cooney KA, Germline 
mutations in HOXB13 and prostate-cancer risk. N Engl J Med, 2012. 366(2): p. 
141-9. 
4. Walsh PC and Wilson JD, The induction of prostatic hypertrophy in the dog 
with androstanediol. J Clin Invest, 1976. 57(4): p. 1093-7. 
5. Teske E, Naan EC, van Dijk EM, Van Garderen E, and Schalken JA, Canine 
prostate carcinoma: epidemiological evidence of an increased risk in castrated 
dogs. Mol Cell Endocrinol, 2002. 197(1-2): p. 251-5. 
6. McNeal JE, Redwine EA, Freiha FS, and Stamey TA, Zonal distribution of 
prostatic adenocarcinoma. Correlation with histologic pattern and direction of 
spread. Am J Surg Pathol, 1988. 12(12): p. 897-906. 
7. Suwa T, Nyska A, Haseman JK, Mahler JF, and Maronpot RR, Spontaneous 
lesions in control B6C3F1 mice and recommended sectioning of male accessory 
sex organs. Toxicol Pathol, 2002. 30(2): p. 228-34. 
8. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, 
Maxson RE, Sucov HM, and Roy-Burman P, Generation of a prostate 
epithelial cell-specific Cre transgenic mouse model for tissue-specific gene 
ablation. Mech Dev, 2001. 101(1-2): p. 61-9. 
9. Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson 
EG, Shen MM, Matusik RJ, Hayward SW, and Bhowmick NA, Stromal 
transforming growth factor-beta signaling mediates prostatic response to 
androgen ablation by paracrine Wnt activity. Cancer Res, 2008. 68(12): p. 4709-
18. 
10. Rao V, Heard JC, Ghaffari H, Wali A, Mutton LN, and Bieberich CJ, A 
Hoxb13-driven reverse tetracycline transactivator system for conditional gene 
expression in the prostate. Prostate, 2012. 72(10): p. 1045-51. 
11. Birbach A, Use of PB-Cre4 mice for mosaic gene deletion. PLoS One, 2013. 8(1): 
p. e53501. 
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai 
Y, Isaacs WB, and Nelson WG, Inflammation in prostate carcinogenesis. Nat 
Rev Cancer, 2007. 7(4): p. 256-69. 
13. Lundgren R, Holmquist B, Hesselvik M, and Muntzing J, Treatment of 
prostatitis in the rat. Prostate, 1984. 5(3): p. 277-84. 
14. Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Giarratana 
N, De Carli E, Fibbi B, and Adorini L, Spontaneous and prostatic steroid 
 79 
binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic 
mouse. J Immunol, 2007. 179(3): p. 1559-67. 
15. Coffey DS, Similarities of prostate and breast cancer: Evolution, diet, and 
estrogens. Urology, 2001. 57(4 Suppl 1): p. 31-8. 
16. Harkonen PL and Makela SI, Role of estrogens in development of prostate 
cancer. J Steroid Biochem Mol Biol, 2004. 92(4): p. 297-305. 
17. Naslund MJ, Strandberg JD, and Coffey DS, The role of androgens and 
estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol, 
1988. 140(5): p. 1049-53. 
18. Sugimura T, Wakabayashi K, Nakagama H, and Nagao M, Heterocyclic 
amines: Mutagens/carcinogens produced during cooking of meat and fish. 
Cancer Sci, 2004. 95(4): p. 290-9. 
19. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, and 
Devere-White R, Inflammation and atrophy precede prostatic neoplasia in a 
PhIP-induced rat model. Neoplasia, 2006. 8(9): p. 708-15. 
20. Ponniah S, Arah I, and Alexander RB, PSA is a candidate self-antigen in 
autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate, 2000. 
44(1): p. 49-54. 
21. Taguchi O, Kojima A, and Nishizuka Y, Experimental autoimmune prostatitis 
after neonatal thymectomy in the mouse. Clin Exp Immunol, 1985. 60(1): p. 
123-9. 
22. Fong L, Ruegg CL, Brockstedt D, Engleman EG, and Laus R, Induction of 
tissue-specific autoimmune prostatitis with prostatic acid phosphatase 
immunization: implications for immunotherapy of prostate cancer. J Immunol, 
1997. 159(7): p. 3113-7. 
23. Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, and 
Cheever MA, Identification of rat prostatic steroid-binding protein as a target 
antigen of experimental autoimmune prostatitis: implications for prostate cancer 
therapy. J Immunol, 1997. 159(1): p. 472-80. 
24. Keetch DW, Humphrey P, and Ratliff TL, Development of a mouse model for 
nonbacterial prostatitis. J Urol, 1994. 152(1): p. 247-50. 
25. Lees JR, Charbonneau B, Hayball JD, Diener K, Brown M, Matusik R, 
Cohen MB, and Ratliff TL, T-cell recognition of a prostate specific antigen is 
not sufficient to induce prostate tissue destruction. Prostate, 2006. 66(6): p. 578-
90. 
26. Shinohara DB, Vaghasia AM, Yu SH, Mak TN, Bruggemann H, Nelson 
WG, De Marzo AM, Yegnasubramanian S, and Sfanos KS, A mouse model of 
chronic prostatic inflammation using a human prostate cancer-derived isolate of 
Propionibacterium acnes. Prostate, 2013. 73(9): p. 1007-15. 
27. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, and Bieberich CJ, 
Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between 
inflammation and neoplasia. Am J Pathol, 2010. 176(5): p. 2259-68. 
28. Elkahwaji JE, Ott CJ, Janda LM, and Hopkins WJ, Mouse model for acute 
bacterial prostatitis in genetically distinct inbred strains. Urology, 2005. 66(4): 
p. 883-7. 
29. Kwon OJ, Zhang L, Ittmann MM, and Xin L, Prostatic inflammation 
enhances basal-to-luminal differentiation and accelerates initiation of prostate 
cancer with a basal cell origin. Proc Natl Acad Sci U S A, 2014. 111(5): p. 
E592-600. 
 80 
30. Sugimura Y, Cunha GR, and Donjacour AA, Morphogenesis of ductal 
networks in the mouse prostate. Biol Reprod, 1986. 34(5): p. 961-71. 
31. Cunha GR, The role of androgens in the epithelio-mesenchymal interactions 
involved in prostatic morphogenesis in embryonic mice. Anat Rec, 1973. 175(1): 
p. 87-96. 
32. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, 
Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, and Shen 
MM, Roles for Nkx3.1 in prostate development and cancer. Genes Dev, 1999. 
13(8): p. 966-77. 
33. Bieberich CJ, Fujita K, He WW, and Jay G, Prostate-specific and androgen-
dependent expression of a novel homeobox gene. J Biol Chem, 1996. 271(50): p. 
31779-82. 
34. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, 
Hayward SW, Cunha GR, Cardiff RD, Shen MM, and Abate-Shen C, 
Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer 
Res, 2002. 62(11): p. 2999-3004. 
35. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, 
Parmigiani G, and Berman DM, Androgen-induced programs for prostate 
epithelial growth and invasion arise in embryogenesis and are reactivated in 
cancer. Oncogene, 2008. 27(57): p. 7180-91. 
36. Zhang TJ, Hoffman BG, Ruiz de Algara T, and Helgason CD, SAGE reveals 
expression of Wnt signalling pathway members during mouse prostate 
development. Gene expression patterns : GEP, 2006. 6(3): p. 310. 
37. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, 
Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, and 
Wilson EL, Molecular signatures of the primitive prostate stem cell niche reveal 
novel mesenchymal-epithelial signaling pathways. PLoS ONE, 2010. 5(9). 
38. Mehta V, Abler LL, Keil KP, Schmitz CT, Joshi PS, and Vezina CM, Atlas of 
Wnt and R-spondin gene expression in the developing male mouse lower 
urogenital tract. Dev Dyn, 2011. 240(11): p. 2548-60. 
39. Mucenski ML, Wert SE, Nation JM, Loudy DE, Huelsken J, Birchmeier W, 
Morrisey EE, and Whitsett JA, beta-Catenin is required for specification of 
proximal/distal cell fate during lung morphogenesis. J Biol Chem, 2003. 278(41): 
p. 40231-8. 
40. Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, Glick A, 
Wysolmerski JJ, and Millar SE, Canonical WNT signaling promotes mammary 
placode development and is essential for initiation of mammary gland 
morphogenesis. Development, 2004. 131(19): p. 4819-29. 
41. Murtaugh LC, Law AC, Dor Y, and Melton DA, Beta-catenin is essential for 
pancreatic acinar but not islet development. Development, 2005. 132(21): p. 
4663-74. 
42. Wells JM, Esni F, Boivin GP, Aronow BJ, Stuart W, Combs C, Sklenka A, 
Leach SD, and Lowy AM, Wnt/beta-catenin signaling is required for 
development of the exocrine pancreas. BMC Dev Biol, 2007. 7: p. 4. 
43. Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, 
Wills M, and Matusik RJ, Activation of beta-Catenin in mouse prostate causes 
HGPIN and continuous prostate growth after castration. Prostate, 2009. 69(3): 
p. 249-62. 
 81 
44. Allgeier SH, Lin TM, Vezina CM, Moore RW, Fritz WA, Chiu SY, Zhang 
C, and Peterson RE, WNT5A selectively inhibits mouse ventral prostate 
development. Dev Biol, 2008. 324(1): p. 10-7. 
45. Huang L, Pu Y, Hu WY, Birch L, Luccio-Camelo D, Yamaguchi T, and 
Prins GS, The role of Wnt5a in prostate gland development. Dev Biol, 2009. 
328(2): p. 188-99. 
46. Wang BE, Wang XD, Ernst JA, Polakis P, and Gao WQ, Regulation of 
epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt 
signaling. PLoS ONE, 2008. 3(5): p. e2186. 
47. Bierie B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T, Taketo 
MM, Cardiff RD, Miyoshi K, Wagner KU, Robinson GW, and 
Hennighausen L, Activation of beta-catenin in prostate epithelium induces 
hyperplasias and squamous transdifferentiation. Oncogene, 2003. 22(25): p. 
3875-87. 
48. Bruxvoort KJ, Charbonneau HM, Giambernardi TA, Goolsby JC, Qian CN, 
Zylstra CR, Robinson DR, Roy-Burman P, Shaw AK, Buckner-Berghuis 
BD, Sigler RE, Resau JH, Sullivan R, Bushman W, and Williams BO, 
Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res, 
2007. 67(6): p. 2490-6. 
49. Li X, Wang Y, Sharif-Afshar A-R, Uwamariya C, Yi A, Ishii K, Hayward 
SW, Matusik RJ, and Bhowmick NA, Urothelial transdifferentiation to 
prostate epithelia is mediated by paracrine TGF-[beta] signaling. Differentiation, 
2009. 77(1): p. 95-102. 
50. Gordon MD and Nusse R, Wnt signaling: multiple pathways, multiple 
receptors, and multiple transcription factors. J Biol Chem, 2006. 281(32): p. 
22429-33. 
51. Aberle H, Bauer A, Stappert J, Kispert A, and Kemler R, beta-catenin is a 
target for the ubiquitin-proteasome pathway. EMBO J, 1997. 16(13): p. 3797-
804. 
52. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, 
Wedlich D, and Birchmeier W, Functional interaction of an axin homolog, 
conductin, with beta-catenin, APC, and GSK3beta. Science, 1998. 280(5363): p. 
596-9. 
53. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, and Costantini F, 
Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative 
regulator of the signaling pathway. Mol Cell Biol, 2002. 22(4): p. 1172-83. 
54. Ontiveros CS, Salm SN, and Wilson EL, Axin2 expression identifies 
progenitor cells in the murine prostate. Prostate, 2008. 68(12): p. 1263-72. 
55. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto 
D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, 
Escobedo J, Fantl WJ, and Williams LT, Elevated expression of axin2 and hnkd 
mRNA provides evidence that Wnt/beta -catenin signaling is activated in human 
colon tumors. Proc Natl Acad Sci U S A, 2001. 98(26): p. 14973-8. 
56. Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, and Kemler R, 
Lack of beta-catenin affects mouse development at gastrulation. Development, 
1995. 121(11): p. 3529-37. 
57. Jin C, McKeehan K, and Wang F, Transgenic mouse with high Cre 
recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. 
Prostate, 2003. 57(2): p. 160-4. 
 82 
58. Lin Y, Liu G, Zhang Y, Hu YP, Yu K, Lin C, McKeehan K, Xuan JW, Ornitz 
DM, Shen MM, Greenberg N, McKeehan WL, and Wang F, Fibroblast 
growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis 
and the acquisition of strict androgen dependency for adult tissue homeostasis. 
Development, 2007. 134(4): p. 723-34. 
59. Jokela T and Vainio S, Conditional tamoxifen Cre induced mutagenesis in the 
embryonic kidney in organ culture. Genesis, 2007. 45(12): p. 757-61. 
60. Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, 
Berman DM, and Lotan TL, PI3K/mTOR signaling regulates prostatic 
branching morphogenesis. Dev Biol, 2011. 360(2): p. 329-42. 
61. Chen H and Bieberich CJ, Structural and functional analysis of domains 
mediating interaction between NKX-3.1 and PDEF. J Cell Biochem, 2005. 
94(1): p. 168-77. 
62. McMullin RP, Mutton LN, and Bieberich CJ, Hoxb13 regulatory elements 
mediate transgene expression during prostate organogenesis and carcinogenesis. 
Dev Dyn, 2009. 238(3): p. 664-72. 
63. Staack A, Donjacour AA, Brody J, Cunha GR, and Carroll P, Mouse 
urogenital development: a practical approach. Differentiation; research in 
biological diversity, 2003. 71(7): p. 402. 
64. Livak KJ and Schmittgen TD, Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 
2001. 25(4): p. 402-8. 
65. Lasnitzki I and Mizuno T, Induction of the rat prostate gland by androgens in 
organ culture. J Endocrinol, 1977. 74(1): p. 47-55. 
66. Brault V, Moore R, Kutsch S, Ishibashi M, Rowitch DH, McMahon AP, 
Sommer L, Boussadia O, and Kemler R, Inactivation of the beta-catenin gene 
by Wnt1-Cre-mediated deletion results in dramatic brain malformation and 
failure of craniofacial development. Development, 2001. 128(8): p. 1253-64. 
67. Badea TC, Wang Y, and Nathans J, A noninvasive genetic/pharmacologic 
strategy for visualizing cell morphology and clonal relationships in the mouse. J 
Neurosci, 2003. 23(6): p. 2314-22. 
68. Yu X, Wang Y, DeGraff DJ, Wills ML, and Matusik RJ, Wnt/beta-catenin 
activation promotes prostate tumor progression in a mouse model. Oncogene, 
2011. 30(16): p. 1868-79. 
69. Doles JD, Vezina CM, Lipinski RJ, Peterson RE, and Bushman W, Growth, 
morphogenesis, and differentiation during mouse prostate development in situ, in 
renal grafts, and in vitro. The Prostate, 2005. 65(4): p. 390. 
70. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, 
Bruseo C, Wood AW, and Shivdasani RA, Small-molecule antagonists of the 
oncogenic Tcf/beta-catenin protein complex. Cancer Cell, 2004. 5(1): p. 91-102. 
71. Sciavolino PJ, Abrams EW, Yang L, Austenberg LP, Shen MM, and Abate-
Shen C, Tissue-specific expression of murine Nkx3.1 in the male urogenital 
system. Dev Dyn, 1997. 209(1): p. 127-38. 
72. Sreenath T, Orosz A, Fujita K, and Bieberich CJ, Androgen-independent 
expression of hoxb-13 in the mouse prostate. Prostate, 1999. 41(3): p. 203-7. 
73. Thomsen MK, Butler CM, Shen MM, and Swain A, Sox9 is required for 
prostate development. Dev Biol, 2008. 316(2): p. 302-11. 
 83 
74. Stanfel MN, Moses KA, Carson JA, Zimmer DB, DeMayo F, Schwartz RJ, 
and Zimmer WE, Expression of an Nkx3.1-CRE gene using ROSA26 reporter 
mice. Genesis, 2006. 44(11): p. 550-5. 
75. Aberle H, Schwartz H, and Kemler R, Cadherin-catenin complex: protein 
interactions and their implications for cadherin function. J Cell Biochem, 1996. 
61(4): p. 514-23. 
76. Truica CI, Byers S, and Gelmann EP, Beta-catenin affects androgen receptor 
transcriptional activity and ligand specificity. Cancer research, 2000. 60(17): p. 
4709. 
77. Bridgewater D, Cox B, Cain J, Lau A, Athaide V, Gill PS, Kuure S, Sainio 
K, and Rosenblum ND, Canonical WNT/beta-catenin signaling is required for 
ureteric branching. Dev Biol, 2008. 317(1): p. 83-94. 
78. Prins GS, Birch L, Habermann H, Chang WY, Tebeau C, Putz O, and 
Bieberich C, Influence of neonatal estrogens on rat prostate development. 
Reprod Fertil Dev, 2001. 13(4): p. 241-52. 
79. Coussens LM and Werb Z, Inflammation and cancer. Nature, 2002. 
420(6917): p. 860-7. 
80. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, 
and Nelson WG, Prostate carcinogenesis and inflammation: emerging insights. 
Carcinogenesis, 2005. 26(7): p. 1170-81. 
81. Platz EA and De Marzo AM, Epidemiology of inflammation and prostate 
cancer. J Urol, 2004. 171(2 Pt 2): p. S36-40. 
82. Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP, Caan 
BJ, and Van Den Eeden SK, Prostatitis, sexually transmitted diseases, and 
prostate cancer: the California Men's Health Study. PLoS One, 2010. 5(1): p. 
e8736. 
83. Nelson WG, De Marzo AM, DeWeese TL, and Isaacs WB, The role of 
inflammation in the pathogenesis of prostate cancer. J Urol, 2004. 172(5 Pt 2): p. 
S6-11; discussion S11-2. 
84. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, and 
Rittmaster RS, The relationship between prostate inflammation and lower 
urinary tract symptoms: examination of baseline data from the REDUCE trial. 
Eur Urol, 2008. 54(6): p. 1379-84. 
85. Yoon BI, Kim S, Han DS, Ha US, Lee SJ, Kim HW, Han CH, and Cho YH, 
Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect 
Chemother, 2012. 18(4): p. 444-50. 
86. Yanamandra K, Alexeyev O, Zamotin V, Srivastava V, Shchukarev A, 
Brorsson AC, Tartaglia GG, Vogl T, Kayed R, Wingsle G, Olsson J, Dobson 
CM, Bergh A, Elgh F, and Morozova-Roche LA, Amyloid formation by the 
pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS One, 2009. 
4(5): p. e5562. 
87. Hochreiter WW, Duncan JL, and Schaeffer AJ, Evaluation of the bacterial 
flora of the prostate using a 16S rRNA gene based polymerase chain reaction. J 
Urol, 2000. 163(1): p. 127-30. 
88. Krieger JN, Riley DE, Vesella RL, Miner DC, Ross SO, and Lange PH, 
Bacterial dna sequences in prostate tissue from patients with prostate cancer and 
chronic prostatitis. J Urol, 2000. 164(4): p. 1221-8. 
 84 
89. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, and Macoska 
JA, Leukocytic promotion of prostate cellular proliferation. Prostate, 2010. 70(4): 
p. 377-89. 
90. Wiseman H and Halliwell B, Damage to DNA by reactive oxygen and nitrogen 
species: role in inflammatory disease and progression to cancer. Biochem J, 1996. 
313 ( Pt 1): p. 17-29. 
91. Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, 
Baroni G, Lanciotti M, Serni S, and Chiarugi P, Cancer-associated fibroblasts 
and M2-polarized macrophages synergize during prostate carcinoma progression. 
Oncogene, 2013. 
92. Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, Lin WJ, and Chang 
C, Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating 
Androgen Receptor-Mediated CCL4-STAT3 Signaling. Cancer Res, 2013. 
73(18): p. 5633-46. 
93. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker 
AK, Isaacs WB, and Drake CG, Phenotypic analysis of prostate-infiltrating 
lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res, 2008. 14(11): p. 
3254-61. 
94. Vykhovanets EV, Maclennan GT, Vykhovanets OV, and Gupta S, IL-17 
Expression by macrophages is associated with proliferative inflammatory atrophy 
lesions in prostate cancer patients. Int J Clin Exp Pathol, 2011. 4(6): p. 552-65. 
95. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, 
Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, and Sears CL, 
A human colonic commensal promotes colon tumorigenesis via activation of T 
helper type 17 T cell responses. Nat Med, 2009. 15(9): p. 1016-22. 
96. Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, 
Snyder PW, Svensson RU, Henry MD, Wang HH, and Ratliff TL, An 
inducible model of abacterial prostatitis induces antigen specific inflammatory 
and proliferative changes in the murine prostate. Prostate, 2011. 71(11): p. 1139-
50. 
97. Kwon OJ, Zhang L, Ittmann MM, and Xin L, Prostatic inflammation 
enhances basal-to-luminal differentiation and accelerates initiation of prostate 
cancer with a basal cell origin. Proc Natl Acad Sci U S A, 2013. 
98. Boehm BJ, Colopy SA, Jerde TJ, Loftus CJ, and Bushman W, Acute bacterial 
inflammation of the mouse prostate. Prostate, 2012. 72(3): p. 307-17. 
99. Elkahwaji JE, Zhong W, Hopkins WJ, and Bushman W, Chronic bacterial 
infection and inflammation incite reactive hyperplasia in a mouse model of 
chronic prostatitis. Prostate, 2007. 67(1): p. 14-21. 
100. Rudick CN, Berry RE, Johnson JR, Johnston B, Klumpp DJ, Schaeffer AJ, 
and Thumbikat P, Uropathogenic Escherichia coli induces chronic pelvic pain. 
Infect Immun, 2011. 79(2): p. 628-35. 
101. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, 
Matusik R, Thomas GV, and Sawyers CL, Myc-driven murine prostate cancer 
shares molecular features with human prostate tumors. Cancer Cell, 2003. 4(3): 
p. 223-38. 
102. Thumbikat P, Berry RE, Zhou G, Billips BK, Yaggie RE, Zaichuk T, Sun 
TT, Schaeffer AJ, and Klumpp DJ, Bacteria-induced uroplakin signaling 
mediates bladder response to infection. PLoS Pathog, 2009. 5(5): p. e1000415. 
 85 
103. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons 
BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, 
and Cardiff RD, Animal models of human prostate cancer: the consensus report 
of the New York meeting of the Mouse Models of Human Cancers Consortium 
Prostate Pathology Committee. Cancer Res, 2013. 73(9): p. 2718-36. 
104. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola 
M, and Li X, Distinct cytokine patterns identified from multiplex profiles of 
murine DSS and TNBS-induced colitis. Inflamm Bowel Dis, 2009. 15(3): p. 
341-52. 
105. Blando JM, Carbajal S, Abel E, Beltran L, Conti C, Fischer S, and 
DiGiovanni J, Cooperation between Stat3 and Akt signaling leads to prostate 
tumor development in transgenic mice. Neoplasia, 2011. 13(3): p. 254-65. 
106. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, 
Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, and De Marzo AM, 
Nuclear MYC protein overexpression is an early alteration in human prostate 
carcinogenesis. Mod Pathol, 2008. 21(9): p. 1156-67. 
107. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti 
MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, and 
Nevalainen MT, Stat3 promotes metastatic progression of prostate cancer. Am J 
Pathol, 2008. 172(6): p. 1717-28. 
108. Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, 
Lotz MT, Yegnasubramanian S, Nelson WG, Dang CV, Xu M, Anele U, 
Koh CM, Bieberich CJ, and De Marzo AM, MYC overexpression induces 
prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial 
cells. PLoS ONE, 2010. 5(2): p. e9427. 
109. Osborne LC, Joyce KL, Alenghat T, Sonnenberg GF, Giacomin PR, Du Y, 
Bergstrom KS, Vallance BA, and Nair MG, Resistin-like molecule alpha 
promotes pathogenic Th17 cell responses and bacterial-induced intestinal 
inflammation. J Immunol, 2013. 190(5): p. 2292-300. 
110. Ivanov, II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, 
Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda 
K, Umesaki Y, Honda K, and Littman DR, Induction of intestinal Th17 cells 
by segmented filamentous bacteria. Cell, 2009. 139(3): p. 485-98. 
111. Quick ML, Wong L, Mukherjee S, Done JD, Schaeffer AJ, and Thumbikat 
P, Th1-Th17 cells contribute to the development of uropathogenic Escherichia 
coli-induced chronic pelvic pain. PLoS ONE, 2013. 8(4): p. e60987. 
112. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, and Yu H, IL-17 can 
promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med, 
2009. 206(7): p. 1457-64. 
113. Zhang Q, Liu S, Ge D, Zhang Q, Xue Y, Xiong Z, Abdel-Mageed AB, 
Myers L, Hill SM, Rowan BG, Sartor O, Melamed J, Chen Z, and You Z, 
Interleukin-17 promotes formation and growth of prostate adenocarcinoma in 
mouse models. Cancer Res, 2012. 72(10): p. 2589-99. 
114. Nadler RB, Koch AE, Calhoun EA, Campbell PL, Pruden DL, Bennett CL, 
Yarnold PR, and Schaeffer AJ, IL-1beta and TNF-alpha in prostatic secretions 
are indicators in the evaluation of men with chronic prostatitis. J Urol, 2000. 
164(1): p. 214-8. 
 86 
115. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, 
and Pienta KJ, CCL2 is a potent regulator of prostate cancer cell migration and 
proliferation. Neoplasia, 2006. 8(7): p. 578-86. 
116. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, and Pienta KJ, CCL2 as an 
important mediator of prostate cancer growth in vivo through the regulation of 
macrophage infiltration. Neoplasia, 2007. 9(7): p. 556-62. 
117. Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F, Pontes 
JE, Leland P, Pastan I, Debinski W, and Puri RK, Interleukin-13 receptors on 
human prostate carcinoma cell lines represent a novel target for a chimeric 
protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J Urol, 
1997. 158(3 Pt 1): p. 948-53. 
118. Debelec-Butuner B, Alapinar C, Varisli L, Erbaykent-Tepedelen B, Hamid 
SM, Gonen-Korkmaz C, and Korkmaz KS, Inflammation-mediated abrogation 
of androgen signaling: An in vitro model of prostate cell inflammation. Mol 
Carcinog, 2012. 
119. Litvinov IV, De Marzo AM, and Isaacs JT, Is the Achilles' heel for prostate 
cancer therapy a gain of function in androgen receptor signaling? J Clin 








Brian W. Simons, DVM        
 
Johns Hopkins University School of Medicine 
Department of Molecular and Comparative Pathobiology 
Koch Cancer Research Building, Room 532 




Education & Training 
  
Postoctoral Fellowship     2014-present    
Johns Hopkins University School of Medicine 
Mentors:  Edward Schaeffer and Barry Nelkin 
 
Ph.D., Pathobiology      2014 
Johns Hopkins University School of Medicine 
Mentor: David Berman 
 
Residency, Veterinary Anatomic Pathology   2004-2007 
Johns Hopkins University School of Medicine   
       
D.V.M.       2004            
Texas A&M University, College Station, TX 
 
B.S., Genetics      2000  
B.A., Philosophy      2000 




Molecular and Clinical Investigations to Reduce the Morbidity of Prostate Cancer 
 Prostate Cancer Foundation Special Challenge Award 
 Performance Period: 07/01/13-06/30/18 
 
CDK5 Alters Immune Response to Prostate Cancer 
Patrick C. Walsh Prostate Cancer Foundation (PI: Nelkin) 
Performance Period: 04/01/12-03/31/15 
 
Designing Polyamide Inhibitors of Twist 1 for Pro-senescence Therapy 
Department of Defense CDMRP (W81XWH-13-1-0182, PI: Tran) 
Performance Period: 07/01/2013-06/30/2014 
 
Structure-Function Studies of Twist1-induced radioresistance in lung cancer 
National Institutes of Healh (R01CA166348, PI: Tran)                       
Performance Period: 08/01/13-05/31/18 
 
 89 
Defining a Role for the Oncogene Beta-Catenin in Prostate Epithelial Growth and 
Invasion 
Department of Defense CDMRP Pre-doctoral Training Award (PC080778, PI: 
Simons)  
Performance Period: 07/01/2009-02/11/2011 
 
Honors and Awards 
 
2014 Poster Award, Honorable Mention, Department of Urology Prostate Cancer 
Research Day, Johns Hopkins University School of Medicine 
2012 First Place Poster Award, 50th Anniversary Year in Review, Department of 
Molecular and Comparative Pathobiology, Johns Hopkins University School 
of Medicine 
2011 Ralph M. Burnett First Place Poster Award, 6th Annual Prostate Research 
Day, Department of Urology, Johns Hopkins University School of Medicine 
2010 3rd place poster, Experimental Disease, American College of Veterinary 
Pathologists Annual Meeting 
2010 Travel award and podium presentation, Society for Basic Urologic Research 
Annual Meeting 
2010 First place award for oral presentation, Pathobiology Graduate Program 
Annual Retreat, Johns Hopkins University School of Medicine  
2010 Award for Excellence in Basic Research, Young Investigator’s Day, 
Department of Pathology, Johns Hopkins University School of Medicine 
2010 John L. Willey First Place Poster Award, 5th Annual Prostate Research Day, 
Department of Urology, Johns Hopkins University School of Medicine 
2009 Award for Excellence in Basic Research, Young Investigator’s Day, 
Department of Pathology, Johns Hopkins University School of Medicine 
2008 Award for Excellence in Basic Research, Young Investigator’s Day, 
Department of Pathology, Johns Hopkins University School of Medicine 
2004 Graduation with honors, College of Veterinary Medicine, Texas A&M 
University 




Buscaglia JM, Simons BW, Prosser BJ, Ruben DS, Giday SA, Magno P, Clarke JO, 
Shin EJ, Kalloo AN, Kantsevoy SV, Gabrielson KL, Jagannath SB, Etanercept, 
a TNF-alpha binding agent, is ineffective in the prevention of post-ERCP 
pancreatitis in canines. Jop 9, 456-67, 2008a. PMCID18648137 
Buscaglia JM, Simons BW, Prosser BJ, Ruben DS, Giday SA, Magno P, Clarke JO, 
Shin EJ, Kalloo AN, Kantsevoy SV, Gabrielson KL, Jagannath SB, Severity of 
post-ERCP pancreatitis directly proportional to the invasiveness of 
endoscopic intervention: a pilot study in a canine model. Endoscopy 40, 506-
12, 2008b. PMCID18478511 
Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, 
Parmigiani G, Berman DM, Androgen-induced programs for prostate 
epithelial growth and invasion arise in embryogenesis and are reactivated in 
cancer. Oncogene 27, 7180-91, 2008. PMCID18794802 
 90 
Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, Pandiyan K, Briggs KJ, 
Zhang W, Argani P, Simons B, Yu W, Matsui W, Van Criekinge W, Rassool 
FV, Zambidis E, Schuebel KE, Cope L, Yen J, Mohammad HP, Cheng L, 
Baylin SB, Cancer-related epigenome changes associated with 
reprogramming to induced pluripotent stem cells. Cancer Res 70, 7662-73, 
2010. PMCID20841480 
Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-
Ross M, Dimeric naphthoquinones, a novel class of compounds with prostate 
cancer cytotoxicity. BJU Int 108, 447-54, 2010a. PMCID21176082 
Ross AE, Marchionni L, Phillips TM, Miller RM, Hurley PJ, Simons BW, Salmasi 
AH, Schaeffer AJ, Gearhart JP, Schaeffer EM, Molecular effects of genistein on 
male urethral development. J Urol 185, 1894-8, 2010b. PMCID21421236 
Zhang W, Zeng X, Briggs KJ, Beaty R, Simons B, Chiu Yen RW, Tyler MA, Tsai 
HC, Ye Y, Gesell GS, Herman JG, Baylin SB, Watkins DN, A potential tumor 
suppressor role for Hic1 in breast cancer through transcriptional repression of 
ephrin-A1. Oncogene 29, 2467-76, 2010. PMCID20154726 
Boylan NJ, Kim AJ, Suk JS, Adstamongkonkul P, Simons BW, Lai SK, Cooper 
MJ, Hanes J, Enhancement of airway gene transfer by DNA nanoparticles 
using a pH-responsive block copolymer of polyethylene glycol and poly-L-
lysine. Biomaterials 33, 2361-71, 2011. PMCID22182747 
Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM, 
Lotan TL, PI3K/mTOR signaling regulates prostatic branching 
morphogenesis. Dev Biol 360, 329-42, 2011. PMCID22015718 
Shabbeer S, Williams SA, Simons BW, Herman JG, Carducci MA, Progression of 
prostate carcinogenesis and dietary methyl donors: temporal dependence. 
Cancer Prev Res (Phila) 5, 229-39, 2011. PMCID22139053 
Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer 
EM, Sox9 is required for prostate development and prostate cancer initiation. 
Oncotarget 3, 651-63, 2012. PMCID22761195 
Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, 
Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, 
Platz EA, Berman DM, Schaeffer EM, Secreted protein, acidic and rich in 
cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers 
and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A 109, 
14977-82, 2012. PMCID22927397 
Kahlert U, Maciaczyk D, Doostkam S, Orr BA, Simons B, Bogiel T, Reithmeier T, 
Prinz M, Schubert J, Niedermann G, Brabletz T, Eberhart CG, Nikkhah G, 
Maciaczyk J, Activation of canonical WNT/beta-catenin signaling enhances in 
vitro motility of glioblastoma cells by activation of ZEB1 and other activators 
of epithelial-to-mesenchymal transition. Cancer Lett 2012. PMCID22652173 
Kedziorek DA, Hofmann LV, Fu Y, Gilson WD, Cosby KM, Kohl B, Barnett BP, 
Simons BW, Walczak P, Bulte JW, Gabrielson K, Kraitchman DL, X-ray-
visible microcapsules containing mesenchymal stem cells improve hind limb 
perfusion in a rabbit model of peripheral arterial disease. STEM CELLS 30, 
1286-96, 2012. PMCID22438076 
Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, 
Schaeffer EM, Wnt signaling though beta-catenin is required for prostate 
lineage specification. Dev Biol 2012. PMCID22960283 
 91 
Clayton LA, Stamper MA, Whitaker BR, Hadfield CA, Simons B, Mankowski JL, 
Mycobacterium abscessus pneumonia in an Atlantic bottlenose dolphin 
(Tursiops truncatus). J Zoo Wildl Med 43, 961-5, 2012. PMCID23272373 
Carvalho FL, Simons BW, Antonarakis ES, Rasheed Z, Douglas N, Villegas D, 
Matsui W, Berman DM, Tumorigenic potential of circulating prostate tumor 
cells. Oncotarget 4, 413-21, 2013. PMCID23530114 
Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, 
Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff 
RD, Animal Models of Human Prostate Cancer: The Consensus Report of the 
New York Meeting of the Mouse Models of Human Cancers Consortium 
Prostate Pathology Committee. Cancer Res 73, 2718-2736, 2013. 
PMCID23610450 
Pascal LE, Ai J, Masoodi KZ, Wang Y, Wang D, Eisermann K, Rigatti LH, 
O'Malley KJ, Ma HM, Wang X, Dar JA, Parwani AV, Simons BW, Ittman 
MM, Li L, Davies BJ,Wang Z: Development of a Reactive Stroma Associated 
with Prostatic Intraepithelial Neoplasia in EAF2 Deficient Mice. PLoS One 
2013; 8:e79542. PMCID:3832612 
Yang M, Yu T, Wang YY, Lai SK, Zeng Q, Miao B, Tang BC, Simons BW, Ensign 
L, Juang CY, Liu G, Chan WY, Mert O, Wood J, Fu J, McMahon MT, Wu TC, 
Hung CF, Hanes J, Vaginal delivery of paclitaxel via mucus-penetrating 
nanoparticles suppresses cervical tumor growth.  Advanced Healthcare 
Materials Dec 16 2013.  PMID: 24339398 
 
In Press 
Saxema P, Haito-Chavez Y, Kord A, Venkata S, Aguila G, Zhang M, Zhang F, 
Peng J, Gabrielson K, Simons BW, Kalloo AN, Khashab MA, A Novel 
Viscous Dissecting Gel is Safe, Simple and Rapid for Endoscopic Submucosal 
Dissection: A Prospective Survival Study in a Porcine Model.  Endoscopy 
Yang M, Yu T, Wang YY, Tang BC, Zeng Q, Simons BW, Fu J, Juang CY, Lai S, 
Wu TC, Hung CF, Hanes J, Intraperitoneal Delivery of Paclitaxel by 
Poly(ether-anhydride) Microspheres Effectively Suppresses Tumor Growth in 





Simons BW, Miller R, Jabbari J, Ross AE, Hurley PJ, Schaeffer EM, A Murine 
Model of Prostate Cancer Bone Metastasis In a Syngeneic Immunocompetent 
Host 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
Simons BW, Alme A, Drake CG, Nelkin BD, Cyclin-Dependent Kinase 5 (CDK5) 
Controls Prostate Cancer Metastasis in Vivo and Alters Tumor Immune 
Response 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
Hurley PJ, Simons BW, Hughes RM, Miller R, Kimuara Y, Haffner MC, Esopi D, 
Yegnasubramanian S, Erho N, Vergara IA, Davicioni E, Faraj S, Netto G, 
 92 
Schaeffer EM, Sparl1 is an Androgen Regulated Tumor Supressor in the 
Prostate. 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
Hurley PJ, Sundi D, Simons BW, Hughes RM, Yan G, Gielzak M, Kasch-Semenza 
L, Berman DM, Isaacs SD, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM, 
Germline Variants in the ARPORIN Aspartic Acid Repeat Domain and 
Adverse Prostate Cancer Outcomes. 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
 
2013 
Simons BW, Galindo-Cardiel I, Ward, J, Brayton CF, Berman DM.  An optimized 
method of murine prostate trimming for histologic analysis 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
Casey KM, Miller R, Jabbari J, Brayton CF, Hurley PJ, Schaeffer EM, Simons BW, 
Effect of Background Strain on Prostate Cancer Progression in Hi-Myc Mice 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
 
2012 
Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, 
Schaeffer EM, Wnt signaling though beta-catenin is required for prostate 
lineage specification 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
 Johns Hopkins Dept of Molecular and Comparative Pathobiology Year in 
Review 
Simons BW, Durham N, Bruno T, Grosso J, Schaeffer AJ, Ross AE, Hurley PJ, 
Berman DM, Drake CG, Thumbikat P, and Schaeffer EM.  Chronic Prostatitis 
Promotes Prostate Cancer Progression in a Mouse Model 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
 Johns Hopkins Dept of Molecular and Comparative Pathobiology Year in 
Review 
Casey KM, Miller R, Jabbari J, Brayton CF, Hurley PJ, Schaeffer EM, Simons BW, 
Effect of Background Strain on Prostate Cancer Progression in Hi-Myc Mice 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 




Casey KM, Miller R, Jabbari J, Brayton CF, Hurley PJ, Schaeffer EM, Simons BW, 
Effect of Background Strain on Prostate Cancer Progression in Hi-Myc Mice 
 Society for Basic Urologic Research (SBUR) Annual Meeting 
 American College of Veterinary Pathologists (ACVP) Annual Meeting 
 
Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, 
Schaeffer EM, Wnt signaling though beta-catenin is required for prostate 
lineage specification 
 Society for Basic Urologic Research (SBUR) Annual Meeting 
 93 
 Multi-Institutional Prostate Cancer Research Program (SPORE) Meeting 
 
Simons BW, Durham N, Bruno T, Grosso J, Schaeffer AJ, Ross AE, Hurley PJ, 
Berman DM, Drake CG, Thumbikat P, and Schaeffer EM.  Chronic Prostatitis 
Promotes Prostate Cancer Progression in a Mouse Model 
 Multi-Institutional Prostate Cancer Research Program (SPORE) Meeting 
 Johns Hopkins Mouse Phenotyping Conference 
 
Simons BW, Galindo-Cardiel I, Brayton CF, An Optimized Method of Murine 
Prostate Trimming for Histologic Analysis 
 Johns Hopkins Mouse Phenotyping Conference 
 
2010 
Simons BW, Galindo-Cardiel I, Brayton CF, An Optimized Method of Murine 
Prostate Trimming for Histologic Analysis 
 American Association for the Advancement of Laboratory Animal Science 
(AALAS) annual meeting 
 American College of Veterinary Pathology (ACVP) Annual Meeting 
 
Simons BW, Thumbikat P, Schaeffer EM, A Mouse Model of Chronic Prostatitis 
Using Human Prostatic Bacterial Isolates 
 Society for Basic Urologic Research (SBUR) Annual Meeting 
 American Association for the Advancement of Laboratory Animal Science 
(AALAS) annual meeting 
 American College of Veterinary Pathology (ACVP) Annual Meeting 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
 
Simons BW, Schaeffer EM, Marchionni L, Berman DM, Wnt Signaling is 
Required for Prostate Induction in the Urogenital Sinus 
 Department of Defence Prostate Cancer Research Program Meeting (DOD 
PCRP-IMPACT) 
 American College of Veterinary Pathology (ACVP) Annual Meeting 
 Society for Developmental Biology Annual Meeting 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
 
Mobley JL, Simons BW, Wack A, Bronson E, Montali RJ, Pathologic Features of 
an Outbreak of Avian Mycobacteriosis in a Captive Population of Waterfowl 
 American College of Veterinary Pathology (ACVP) Annual Meeting 
 
2009 
Simons BW, Schaeffer EM, Marchionni L, Berman DM, Wnt Signaling is 
Required for Prostate Induction in the Urogenital Sinus 





Simons BW, Brayton CF, Berman DM, New Methods for Assessing Murine 
Prostate Development 
 American College of Veterinary Pathologists (ACVP) Annual Meeting 
 John Hopkins Sidney Kimmel Cancer Center Fellows Research Day 
 Johns Hopkins Brady Institute Prostate Cancer Research Day 
 Johns Hopkins Mouse Phenotyping Conference 
 
2006 
Simons BW, Scorpio D, Huso D, Nasal Aspergillosis in a Long-Evans Rat 
 American College of Veterinary Pathologists (ACVP) Annual Meeting 
 Johns Hopkins Dept of Molecular and Comparative Pathobiology Year in 
Review 
 
Brayton CF, Li T, Gluckman T, Simons BW, Trembley S, Forbes N, Notch 
Pathway Factors in Cancer and Alzheimer’s Disease 
 American College of Veterinary Pathologists (ACVP) Annual Meeting 
 
2005 
Simons BW, Clayton LA, Stamper MA, Whitaker BR, Hadfield CA, Mankowski 
JL, Mycobacterium abscessus pneumonia in an Atlantic bottlenose dolphin  




Faculty, Workshop on Phenotyping Mouse Models of Lung Disease, The Jackson 
Laboratory “Histopathology of mouse models of lung disease” September 20-
24, 2009. 
Guest Lecturer, Basic Research, Department of Defense Center for Prostate 
Disease Research “A functional requirement for the oncogene beta-catenin in 
prostate morphogenesis” March 25, 2009. 
 
Manuscript Peer Review 
 
Infection, Genetics, and Evolution (2014) 
Life Sciences (2013) 
British Journal of Urology International (2012) 
Journal of Pathology (2012) 
Carcinogenesis (2012) 
Current Molecular Medicine (2010) 
 
Teaching Activities (course title; location, dates, role) 
 
Mouse Pathobiology and Phenotyping Short Course, Johns Hopkins School of 
Medicine, 2010-2013, Laboratory instructor 
Toxicologic Pathology; Johns Hopkins School of Public Health, 2006-2013 
Guest Lecturer, "Toxicologic pathology of the male reproductive tract" 
 95 
Comparative Pathobiology and Genetically Engineered Mice, Spring 2010 and 
2008, Guest Lecturer, “Comparative Anatomy and Pathology of the 
Reproductive System”  
Pathology For Graduate Students; Johns Hopkins School of Medicine, September 
2008, 2009, and 2010, Histology of neoplasia lab instructor 
Pathobiology and Disease Mechanisms; Johns Hopkins School of Medicine, 
Spring 2008, Teaching assistant 
Pathology For Graduate Students; Johns Hopkins School of Medicine, Spring 
2006 Necropsy Lab, designed and implemented a lab (8 hours contact time) to 
teach rodent anatomy and tissue trimming for histology 
Principles of Animal Pathology; Johns Hopkins School of Medicine, Fall 2005 




2012 NIDDK Short-Term Education Program for Underrepresented Persons 
(STEP-UP) – Supervised the research of an undergraduate student for a two 
month project in the lab of Dr. Edward Schaeffer (Michael Lopresti, 
Investigating the differences in chronic bacterial prostatitis caused by CP1 
and NU14 strains) 
2011 NIDDK Short-Term Education Program for Underrepresented Persons 
(STEP-UP) – Designed and supervised the research project of an 
undergraduate student for a two month project in the lab of Dr. David 
Berman (Anna Miglioretti, Improvement of transduction efficiency in mouse 
primary prostate cells) 
2011 Designed and supervised the research projects of a veterinary pathology 
extern student for a three month project in comparative mouse pathology 
(Kerriann Casey, Effect of background strain on prostate cancer progression 
in Hi-Myc mice) 
2011 Designed and supervised the research project of a medical student for a 
three month project in the lab of Dr. Edward Schaeffer (Spencer Lake, The 
Role of Wnt Signaling in Human Prostate Cancer Tumor Initiating Cells) 
2010 Designed and supervised the research projects of a veterinary pathology 
extern student for a three month project in comparative mouse pathology 
(Ivan Galindo-Cardiel, An optimized method of prostate trimming for 
histologic analysis) 
2010 Designed and supervised the research project of a veterinary pathology 
extern for three months  (Jessica Mobley, Pathologic features of an outbreak 
of avian mycobacteriosis in a captive population of waterfowl) 
2010 Designed and supervised the research project of a medical student for a two 
month project in the lab of Dr. Edward Schaeffer 
 
Credentials and Professional Societies 
 
American College of Veterinary Pathologists, board eligible, anatomic pathology 
Maryland veterinary medical and surgical license #5757 




TERMS AND CONDITIONS 
Dec 21, 2012 
 
 
This is a License Agreement between Brian Simons ("You") and Elsevier ("Elsevier") provided by 
Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and 
conditions provided by Elsevier, and the payment terms and conditions. 
 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Brian Simons 
Customer address 1550 Orleans Street CRB2-532 
  Baltimore, MD 21295 
License number 3053361227605 
License date Dec 20, 2012 
Licensed content publisher Elsevier 
Licensed content publication Developmental Biology 
Licensed content title Wnt signaling though beta-catenin is required for 
prostate lineage specification 
Licensed content author Brian W. Simons, Paula J. Hurley, Zhenhua Huang, 
Ashley E. Ross, Rebecca Miller, Luigi Marchionni, David 
M. Berman, Edward M. Schaeffer 
Licensed content date 15 November 2012 
Licensed content volume number 371 
Licensed content issue number 2 
Number of pages 10 
Start Page 246 
End Page 255 
Type of Use reuse in a thesis/dissertation  
Portion full article  
Format print  




Will you be translating? No  
Order reference number   
Title of your thesis/dissertation Development and application of new systems for 
modeling murine prostatic development and disease  
Expected completion date Dec 2013  
 97 
Estimated size (number of pages) 75  
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD  
VAT/Local Sales Tax 0.0 USD / 0.0 GBP 
Total 0.00 USD   
   
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in connection with 
completing this licensing transaction, you agree that the following terms and conditions apply to 
this transaction (along with the Billing and Payment terms and conditions established by 
Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and 
that are available at any time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the 
terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in 
our publication with credit or acknowledgement to another source, permission must also be sought 
from that source.  If such permission is not obtained then that material may not be included in your 
publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or 
in a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, 
Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY 
COPYRIGHT OWNER].” Also Lancet special credit - “Reprinted from The Lancet, Vol. number, 
Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which permission is 
hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions 
and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. 
(Please contact Elsevier at permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this instance, please be 
advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of 
(i) the license details provided by you and accepted in the course of this licensing transaction, (ii) 
these terms and conditions and (iii) CCC's Billing and Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately 
upon issuance of the license at the end of the licensing process for the transaction, provided that 
you have disclosed complete and accurate details of your proposed use, no license is finally 
effective unless and until full payment is received from you (either by publisher or by CCC) as 
provided in CCC's Billing and Payment terms and conditions.  If full payment is not received on a 
timely basis, then any license preliminarily granted shall be deemed automatically revoked and 
shall be void as if never granted.  Further, in the event that you breach any of these terms and 
  
 98 
conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically 
revoked and shall be void as if never granted.  Use of materials as described in a revoked license, 
as well as any use of the materials beyond the scope of an unrevoked license, may constitute 
copyright infringement and publisher reserves the right to take any and all action to protect its 
copyright in the materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their 
respective officers, directors, employees and agents, from and against any and all claims arising 
out of your use of the licensed material other than as specifically authorized pursuant to this 
license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or 
transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing signed 
by both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase 
order, acknowledgment, check endorsement or other writing prepared by you, which terms are 
inconsistent with these terms and conditions or CCC's Billing and Payment terms and 
conditions.  These terms and conditions, together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein), comprise the entire agreement between you and 
publisher (and CCC) concerning this licensing transaction.  In the event of any conflict between 
your obligations established by these terms and conditions and those established by CCC's Billing 
and Payment terms and conditions, these terms and conditions shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this 
License at their sole discretion, for any reason or no reason, with a full refund payable to 
you.  Notice of such denial will be made using the contact information provided by you.  Failure to 
receive such notice will not alter or invalidate the denial.  In no event will Elsevier or Copyright 
Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a 
result of a denial of your permission request, other than a refund of the amount(s) paid by you to 
Elsevier and/or Copyright Clearance Center for denied permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only unless 
your license was granted for translation rights. If you licensed translation rights you may only 
translate this content into the languages you requested. A professional translator must perform all 
translations and reproduce the content word for word preserving the integrity of the article. If this 
license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all 
languages. 
16. Website: The following terms and conditions apply to electronic reserve and author websites: 
Electronic reserve: If licensed material is to be posted to website, the web site is to be password-
protected and made available only to bona fide students registered on a relevant course if: 
This license was made in connection with a course, 
This permission is granted for 1 year only. You may obtain a license for future website posting,  
All content posted to the web site must maintain the copyright information line on the bottom of 
each image,  
 99 
A hyper-text must be included to the Homepage of the journal from which you are licensing 
athttp://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books 
athttp://www.elsevier.com , and 
Central Storage: This license does not include permission for a scanned version of the material to 
be stored in a central repository such as that provided by Heron/XanEdu. 
17. Author website  for journals with the following additional clauses: 
All content posted to the web site must maintain the copyright information line on the bottom of 
each image, and the permission granted is limited to the personal version of your paper. You are 
not allowed to download and post the published electronic version of your article (whether PDF or 
HTML, proof or final version), nor may you scan the printed edition to create an electronic version. 
A hyper-text must be included to the Homepage of the journal from which you are licensing 
athttp://www.sciencedirect.com/science/journal/xxxxx . As part of our normal production 
process, you will receive an e-mail notice when your article appears on Elsevier’s online service 
ScienceDirect (www.sciencedirect.com). That e-mail will include the article’s Digital Object 
Identifier (DOI). This number provides the electronic link to the published article and should be 
included in the posting of your personal version. We ask that you wait until you receive this e-mail 
and have the DOI to do any posting.  
Central Storage: This license does not include permission for a scanned version of the material to 
be stored in a central repository such as that provided by Heron/XanEdu. 
18. Author website for books with the following additional clauses:  
Authors are permitted to place a brief summary of their work online only. 
A hyper-text must be included to the Elsevier homepage at http://www.elsevier.com . All content 
posted to the web site must maintain the copyright information line on the bottom of each image. 
You are not allowed to download and post the published electronic version of your chapter, nor 
may you scan the printed edition to create an electronic version. 
Central Storage: This license does not include permission for a scanned version of the material to 
be stored in a central repository such as that provided by Heron/XanEdu. 
19. Website (regular and for author): A hyper-text must be included to the Homepage of the 
journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx.  or 
for books to the Elsevier homepage at http://www.elsevier.com 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be published 
commercially, please reapply for permission. These requirements include permission for the 
Library and Archives of Canada to supply single copies, on demand, of the complete thesis and 
include permission for UMI to supply single copies, on demand, of the complete thesis. Should 
your thesis be published commercially, please reapply for permission. 
21. Other Conditions: 
  
v1.6 
 
 
